

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Reporting Quality of Randomised Controlled Trial Abstracts on Age-Related Macular Degeneration Health Care – A Cross Sectional Quantification of the Adherence to CONSORT Abstract Reporting Recommendations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021912
Article Type:	Research
Date Submitted by the Author:	25-Jan-2018
Complete List of Authors:	Baulig, Christine; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Krummenauer, Frank; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Geis, Berit; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Tulka, Sabrina; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Knippschild, Stephanie; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University, Departement of Medicine
Keywords:	reporting quality, Abstract, randomized controlled trial, CONSORT, age related macula degeneration

SCHOLARONE™
Manuscripts

Only

1
2
3 **Systematic review of reporting quality of Randomised Controlled Trial Abstracts on**
4 **Age-Related Macular Degeneration Health Care – A Cross Sectional Quantification of**
5 **the Adherence to CONSORT Abstract Reporting Recommendations**
6
7

8
9 Christine Baulig, Frank Krummenauer, Berit Geis, Sabrina Tulka, Stephanie Knippschild

10
11
12 Corresponding author:

13 JProf Christine Baulig MSc
14 Institute for Medical Biometry and Epidemiology
15 Faculty of Health, Witten/Herdecke University
16 Alfred-Herrhausen-Straße 50
17 58448 Witten, Germany
18 Phone: +49 (0)2302 926 782
19 E-mail: Christine.Baulig@uni-wh.de
20
21

22
23 Co-Authors:

24
25 Prof Frank Krummenauer
26 Institute for Medical Biometry and Epidemiology
27 Faculty of Health, Witten/Herdecke University
28 Alfred-Herrhausen-Straße 50
29 58448 Witten, Germany
30

31 MSc Berit Geis
32 Institute for Medical Biometry and Epidemiology
33 Faculty of Health, Witten/Herdecke University
34 Alfred-Herrhausen-Straße 50
35 58448 Witten, Germany
36
37

38 MSc Sabrina Tulka
39 Institute for Medical Biometry and Epidemiology
40 Faculty of Health, Witten/Herdecke University
41 Alfred-Herrhausen-Straße 50
42 58448 Witten, Germany
43

44 Dr Stephanie Knippschild
45 Institute for Medical Biometry and Epidemiology
46 Faculty of Health, Witten/Herdecke University
47 Alfred-Herrhausen-Straße 50
48 58448 Witten, Germany
49
50

51
52
53 **Word count: 3.706**
54
55
56
57
58
59
60

1
2
3 Objective: To assess the reporting quality of RCT abstracts on AMD health care, to evaluate
4 the adherence to the CONSORT statement's recommendations on minimum abstract
5 information and to identify journal characteristics associated with abstract reporting quality.
6

7
8 Design: Cross-sectional evaluation of RCT abstracts on AMD health care
9

10 Methods: A PubMed search was implemented to identify RCT abstracts on AMD health care
11 published in English language between 01/2004 and 12/2013. Data extraction was
12 performed by two parallel readers independently by means of a documentation format in
13 accordance with the 16 items of the CONSORT checklist for abstracts. The total number of
14 criteria fulfilled by an abstract was derived as primary endpoint of the investigation, incidence
15 rate ratios (IRRs) with un-adjusted 95% confidence intervals (95% CI) were estimated by
16 means of multiple Poisson regression to identify journal and article characteristics
17 (publication year, multicentre design, structured abstract recommendations, effective sample
18 size, word count limits and journal impact factor) possibly associated with the total number of
19 fulfilled items.
20
21
22
23
24

25
26 Study characteristics: 136 of 673 identified abstracts (published in 36 different journals)
27 fulfilled all eligibility criteria.
28

29
30 Results: The median number of fulfilled items was 7 (95% CI 7; 8). No abstract reported all
31 16 recommended items; the maximum total number was 14, the minimum 3 of 16 items.
32 Multivariate analysis only demonstrated a journal's word count limitation (>250 vs ≤ 250) as
33 being significantly associated with a better reporting of abstracts (Incidence Rate Ratio (IRR)
34 1.152, 95% CI 1.010; 1.0314).
35
36

37
38 Conclusions: Reporting quality of RCT abstracts on AMD investigations showed a
39 considerable potential for improvement to meet the CONSORT abstract reporting
40 recommendations. Furthermore, word count limits for abstracts of 250 were identified as a
41 significant determinant of the overall abstract reporting quality.
42
43

44 Key Words: RCT, structured abstract, CONSORT statement, reporting quality
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Reporting quality of RCT abstracts on AMD therapy has not been assessed so far.
- The cross-sectional inclusion of all published RCT abstracts on AMD health care without selection of journals ensures maximum possible representativeness.
- Data extraction and evaluation were performed by two independent readers with long-term experience in clinical trial methodology and reporting bias evaluation.

- The readers were not blinded to the journal and publication period so the possibility of reader bias cannot be ruled out entirely.
- Journal characteristics such as formal word count limitations could only be considered as far as published by the journals; the individual reviewing processes underlying the 136 abstracts might have taken additional influence on the actual abstract presentations.

Funding: This work was supported by the Internal Research Foundation Initiative of the Witten / Herdecke University's Faculty of Health, comprising a one-year research position for SK (grant number IFF 2016-001).

Competing interests

The authors declare that they have no competing interests. From the perspective of Good Scientific Practice the authors state, that parts of this manuscript will be presented orally and by means of a congress abstract to be submitted to the 2018 annual meeting of the German Ophthalmic Surgeons (DOC congress, Nuremberg, June 2018).

INTRODUCTION

Randomised controlled trials (RCT) are considered as optimum origin of evidence and have the highest grade of research designs[1, 2]. Frequently, readers of articles reporting on RCT start by screening the content of the abstract first, which subsequently guides the decision whether or not to obtain and read the entire article[3]. In addition to an overwhelming day-to-day workload, a steadily increasing number of publications and limited access to many full-text articles enforce health care providers to build their health care decisions on information in abstracts[4]. Thus, abstracts of RCTs should contain accurate and clear information about implementation, evaluation, findings and synopsis of the clinical trial[5].

Regarding the methodological details, there was no standardised reporting requirement before the Consolidated Standards of Reporting Trials (CONSORT) were established in 1996[6] and revised in 2001[7] and 2010[8, 9], respectively. In order to prevent discrepancies between full-text articles and abstracts, as well as to improve the reporting quality of abstracts, an extension to the CONSORT Statement was published in 2008[5]. This statement contains 17 items comprising eight sections: title, authors' details (specific to conference abstracts), trial design, methods (including participants, interventions, objectives, defined primary outcome, randomisation, blinding), results (numbers randomised, recruitment, numbers analysed, outcomes, harms), conclusions, trial registration and declaration of funding[5]. This enumeration "provides a minimum list of essential items, that authors should consider when reporting the main results of a randomized trial in any journal or conference abstract"[5].

Several studies have been conducted to evaluate the quality of abstract reporting in general medical journals[10-14] or specific fields of medicine such as health care[15], anaesthesia[16], traditional Chinese medicine[17], HIV/AIDS[3], paediatrics[18], dentistry[19-22] and oncology[23]. These studies thoroughly demonstrated, that there is still a need for optimisation in the reporting of RCT abstracts.

To our knowledge, the reporting quality of RCT abstracts in the field of ophthalmology and especially regarding the treatment of age-related macular degeneration (AMD) has not been assessed yet. AMD is a common eye disease and the leading cause for vision loss among people 50 years of age and older[24], having led to increasing research need on therapeutic concepts and thereby to an increasing number of RCTs on AMD during the past decade. Therefore, the objectives of the present systematic review were to assess the reporting quality of RCT abstracts in AMD health care, to evaluate the adherence to the CONSORT statement's recommendations on minimum abstract information and to identify journal characteristics associated with this parameterisation of abstract reporting quality.

METHODS

Study design

Cross-sectional evaluation of RCT abstracts on AMD health care published between 2004 and 2013 was implemented; to identify eligible RCT publication abstracts, a systematic review of abstracts was performed without any restrictions of publishing journals, according to the PRISMA reporting guidance (see online supplementary material for PRISMA checklist).

Data sources and search strategy

A MEDLINE/Pubmed search for all RCTs published between 2004 and 2013 was performed. The search strategy used the MeSH terms “randomised controlled trial” as publication type and “macular degeneration” as term in title / abstract and was limited to the publication date (2004/01/01 to 2013/12/31) as well as to English as publication language. The publication period was limited in order to reflect the period five years before and after the publication of the extension of CONSORT in 2008. The search was carried out on 2015/09/24 as can be reproduced by online audit trail documentation (supplementary material).

Study selection

Only abstracts reporting on age-related macular degeneration (AMD) health care were considered and then investigated for indications of an underlying RCT design: we included abstracts in which the allocation of participants to interventions was described by the words “random”, “randomly”, “randomised”, “randomisation” or any other terminology suggesting that the participants were randomly distributed to treatment arms. Reports not associated with AMD therapy, without reference to randomisation or an obviously retrospective study design, economic analyses, diagnostic or screening tests, questionnaire reporting, study protocols, observational studies, editorials or letters were excluded as well as reviews, meta-analyses and non-human studies. Two parallel reviewers (CB, SK) independently selected the abstracts; disagreement about which abstracts had to be included was resolved by discussion and consensus, reasons for article exclusion were documented.

Data extraction

1
2
3 A pilot study was performed with randomly selected abstracts concerning cataract surgery to
4 identify problems and solve discrepancies in data collection[25]. The data extraction was
5 performed independently by two parallel reviewers (CB, SK) using the previously created and
6 pretested data extraction and documentation form in accordance to the items of the
7 CONSORT checklist for abstracts[5]. Each item had a “yes”/“no” rating indicating whether the
8 authors had reported this item or not. Only the “authors’ details” item concerning contact
9 details of the corresponding authors was excluded from the assessment, since this item is
10 specific to conference abstracts. For the “outcomes” item two sub-items were evaluated – as
11 required by the CONSORT Statement: 1) primary outcome result presented for each group /
12 arm, 2) for primary outcome, effect size reported for trials with binary outcome resp. with
13 continuous outcome and the precision of effect side (confidence interval (CI)). Only if both
14 criteria were met, a correct reporting of the outcome results items was ascertained. For the
15 “conclusions” item also two sub-items had to be reported: 1) consistency with the reported
16 results and 2) discussion of benefits of and harms from the intervention. Again, only if both
17 sub-items were reported, the correct reporting of “conclusions” was ascertained.
18
19
20
21
22
23
24

25
26 Furthermore the following information on journal and article characteristics were collected:
27 name of the journal, name of first author, year of publication, multicentre design [yes/no],
28 abstract format pre-specified as structured [yes/no], sample size, impact factor of each
29 journal according to the respective publication year. Due to the fact that word count limits in
30 instructions for authors were found to show severe deviations from the number of words
31 actually used in the abstract, both counts were recorded (word count limitation (status 2017);
32 actual words count in the abstract). In addition, since only the current word count
33 specifications of each journal could be found (status 2017), the actual number of words for
34 each abstract was determined and subdivided into two groups [≤ 250 / > 250 words].
35
36
37
38
39
40
41

42 Primary Endpoint and Sample Size Calculation

43
44 The abstract-wise primary endpoint of this investigation was the total absolute number of
45 items (among all 16 considered) reported in the respective abstract. The primary hypothesis
46 of this investigation was that the proportion of RCT publications showing incomplete or
47 invalid abstract information – as documented by a total score < 16 – were at least 50%; the
48 primary hypothesis was then to be evaluated by means of a two-sided exact (binomial
49 distribution) confidence interval for the respective observed proportion.
50
51
52
53

54 Under the assumption of an expected proportion of 50% by means of a two-sided exact
55 confidence interval controlling for a maximum width less than $\pm 10\%$ the sample size
56 calculation resulted in a required number of cases of 97 abstracts (sample size calculation
57
58
59
60

1
2
3 being based on NQuery Advisor® 7.0 for Windows®). Therefore, we decided to evaluate all
4 existing abstracts (N = 136) and did not draw a random sample.
5
6
7

8 9 Exploratory Analysis

10
11 Descriptive analysis of the primary endpoint was based on medians and quartiles, graphical
12 presentation on box whisker plots, accordingly. For each CONSORT abstract item Cohen's
13 kappa (point estimate and one-sided 95% confidence interval) were derived to assess the
14 parallel readers' agreement, respectively. A kappa point estimate of 0.60 or higher was
15 considered as an indication for substantial inter-observer agreement in the evaluation of the
16 respective item.
17
18
19
20
21
22

23 24 Multivariate Analysis

25
26 Incidence rate ratios (IRRs) with 95% confidence intervals (95% CI, not adjusted for
27 multiplicity with regard to the exploratory character of the multivariate analysis) were
28 estimated by means of multiple Poisson regression to identify journal and article
29 characteristics (publication year, multicentre design, structured abstract recommendations,
30 effective sample size, word count limits and journal impact factor) possibly associated with
31 the total number of fulfilled criteria. Poisson regression modelling was performed by
32 backward variable selection via the AIC criterion, considering Likelihood Ratio test p-values <
33 0.05 as indicators of local statistical significance (i.e. model exploration results were not
34 formally adjusted for multiplicity). The multivariate analysis was conducted using "R" version
35 3.4.0 (R Core Team, 2017).
36
37
38
39
40
41
42

43 44 RESULTS

45
46 Out of 673 identified study publications, 15 had to be excluded in the first place, because no
47 abstracts were available (Figure 1). Furthermore 522 publications had to be excluded due to
48 the following facts: study not related to AMD health care (n=376); abstracts without indication
49 for randomisation (n=127); non-comparative trial design (e.g., questionnaire survey,
50 diagnostic evaluation, health economic analyses n=19). In summary, a total of 136 abstracts
51 fulfilling the eligibility criteria were included in the investigation.
52
53
54
55
56

57 58 Characteristics of included abstracts and underlying journals

The search yielded 136 abstracts of which 55 (40%) were published between 2004 and 2008 (pre-CONSORT) and 81 (n=60%) between 2009 and 2013 (post-CONSORT). The abstracts were published in 36 different journals, of which only two (publishing four articles) had no Thomson & Reuter impact factor. The median impact factor of all journals – according to the respective publication year – was 3.125 (interquartile range Q1 2.367; Q3 5.127). Only seven studies (5%) were published in journals with an impact factor of 10 or higher. Most of the publications (32%) were found in “Ophthalmology” (43/136) followed by “British Journal of Ophthalmology” 10% (13/136) and “Retina” 9% (12/136) (Table 1).

Only one journal did not state word count limits for abstracts in the instructions for authors (status 2017). All other 35 journals limited the words in abstracts to a total number between 200 and 500 words (see Table 1). The actual number of words in abstracts varied between 141 (minimum) and 457 (maximum) with a median of 273 words. 70 (51%) studies were single-centre trials with a minimum sample size of 7 participants up to 300 participants (median 46, Q1 28; Q3 10), and 66 (49%) studies were multi-centre trials with a minimum sample size of 25 participants up to 2457 participants (median 223, Q1 117; Q3 494).

Table 1

Listings of journals with at least one AMD RCT abstract considered in the evaluation, total number of publications (N) with abstracts evaluation from the respective journal as well as relative frequency [%] of these abstracts among all abstracts considered in this investigation, 5-years impact factor (Thomson & Reuter, 2016), as well as information on word count limits according to the published instructions for authors of the respective journals (status 2017).

Journal <i>(Journal Title Abbreviation)</i>	N	proportion <i>(%)</i>	5-years IF <i>(2016)</i>	word count limits <i>(words)</i>
Am J Ophthalmol	9	7	4.797	250
Ophthalmology	43	32	7.788	350
Graefes Arch Clin Exp Ophthalmol	4	3	2.274	250
Br J Nutr	1	1	3.784	250
Clin Hemorheol Microcirc	1	1	1.647	200
Atheroscler Suppl	1	1	3.310	250
N Engl J Med	4	3	64.201	250
Retina	12	9	3.779	200
Arch Ophthalmol	5	4	4.372	350
Br J Ophthalmol	13	10	3.466	250

1					
2					
3	Scand J Occup Ther	1	1	1.561	200
4	Acta Ophthalmologica	7	5	2.812	250
5	Eye (Lond)	5	4	2.547	250
6	Nutrients	1	1	4.187	200
7	PLoS One	1	1	3.394	300
8	Nutrition	2	2	3.312	250
9	Curr Med Res Opin	1	1	2.605	250
10	Invest Ophthalmol Vis Sci	4	3	3.786	250
11	Clin Rehabil	1	1	3.026	250
12	Trans Am Ophthalmol Soc	1	1	0.000	250
13	Optometry	3	2	0.000	250
14	Biomedical Papers	1	1	1.160	250
15	J Clin Neurosci	1	1	1.545	250
16	BMJ	1	1	19.355	
17	Proc Natl Acad Sci U S A	1	1	10.414	250
18	JAMA Ophthalmol	1	1	5.425	350
19	Eur J Ophthalmol	1	1	1.161	250
20	Complementary and Alternative Medicines	1	1	2.644	300
21	BMC Ophthalmology	1	1	1.579	350
22	Experimental Eye Research	2	2	3.235	500
23	Current Eye Research	2	2	1.947	300
24	Annals of Nutrition and Metabolism	1	1	2.883	250
25	Lancet	1	1	48.082	300
26	Ophthalmologica	1	1	1.918	250
27	J Ocul Pharmacol Ther	1	1	1.726	250
28	Total	136			
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Overall reporting quality

Table 2 shows the evaluation of CONSORT checklist items as reported in the 136 RCTs. No abstract reported all 16 items. The best abstract reported 14 of 16, the worst 3 of 16 items. The median number of reported items was 7 (95% CI 7; 8). Comparing the pre- and post-CONSORT periods, abstract reporting improved from median 7 (95% CI 6; 7) to median 8 (95% CI 7; 8) reported items. In total, 104 of 136 abstracts (77%) reported 8 items or less, whereas 32 abstracts stated 9 items or more (23%). Best reported items were “interventions” (95% reported) and “objectives” (98%). The worst reporting was on “outcomes” with 0% (Table 2).

Table 2

Adherence of RCTs (N=136) to individual items of the CONSORT checklist for abstracts: declaration of items to be considered in the abstract according to the CONSORT recommendations, evaluation criteria for the respective abstracts, total and relative frequency [%] of abstracts providing information on the respective items according to the evaluation criteria

For peer review only

Item	assessment criteria	absolute and relative frequency of abstracts reporting the item (N = 136) (%)
Title	declaration of the study as randomised	57 (42%)
Trial design	description of the trial design	97 (71%)
Participants	eligibility criteria for participants and setting where data was collected	123 (90%)
Interventions	description / declaration of interventions intended for each group	129 (95%)
Objectives	specific objectives or hypotheses	133 (98%)
Definition primary outcome	explicitly defined primary outcome	95 (70%)
Randomisation	information on the allocation scheme of trials participants to interventions	39 (29%)
Blinding	whether or not participants, caregivers and those assessing the outcomes were blinded to group assignment	59 (43%)
Numbers randomised	number of participants randomised to each group (intended sample sizes)	75 (55%)
Recruitment	trial status (actual sample sizes)	12 (9%)
Numbers analysed	number of participants analysed for each group (effective sample sizes)	30 (22%)
Outcomes	fulfilling both criteria as:	0 (0%)
	– primary outcome for each trial group / trial arm	87 (64%)
	– for primary outcome, effect size and precision (confidence interval) reported (in total)	9 (7%)
	→ effect size and precision (confidence interval) for trials with binary outcome, n=41	3 (7%)
	→ effect size and precision (confidence interval) for trials with continuous outcome, n=95	6 (6%)
Harms	important adverse events of the results	65 (48%)
Conclusions	general interpretation of the results fulfilling both criteria:	23 (17%)
	– consistency with the results reported in the abstract	130 (96%)

	– benefits and harms reported	24 (18%)
Trial registration	registration number and name of trial register	26 (19%)
Funding	source of funding	33 (24%)

Reporting of “general items”

Only 42% (57/136) identified the presented investigation as randomised in the title. 71% (97/136) described the trial design as required (the information “randomised controlled trial” or “multi-centre / single-centre” were not sufficient). Kappa estimates for these items were 0.89 or above.

Reporting of “trial methodology”

Eligibility criteria for participants and for interventions – to be documented for each treatment group – were reported in 90% (123/136) and 95% (129/136), respectively. Similarly, the specific objective or hypothesis was mentioned in 98% (133/136). 70% (95/136) reported a clearly defined primary outcome. Only 29% (39/136) of abstracts stated information on randomisation and 43% (59/136) on blinding. Details about trial status were given in 9% (12/136). The inter-observer agreement on reporting methods (participants, interventions, objectives, definition primary outcome, randomisation, blinding) varied with kappa estimates ranging from 0.55 to 0.81.

Reporting of “results”

Of the 136 abstracts included, 55% (75/136) reported the number of participants randomised to each group, but only 22% (30/136) reported the number of participants analysed for each group. Important adverse events were described in 48% (65/136). As CONSORT recommends three different sub-items for reporting outcomes, this investigation found a total of 64% (87/136) abstracts reporting primary outcome results for each group, but none of the 136 abstracts reported on effect size and confidence interval for the primary outcome in full detail. The proportion of abstracts describing effect size and confidence intervals for primary outcome was 7 % (9/136): 7% (3 out of 41 trials) with binary outcome and 6% (6 out of 95 trials) with continuous outcome. In total, none of the 136 abstracts met both criteria, so the

correct reporting frequency for the “results” indicators was estimated 0%. The respective underlying kappa estimates ranged from 0.51 to 0.85.

Reporting of “conclusions”

Information on a trial registration number was found in 19% (26/136) of the abstract, and a possible funding source was referenced in 24% (33/136). Correct interpretations of the results in the “conclusions” section as recommended by CONSORT were available in 17% (23/136): 96 % (130/136) of the abstracts reported adequately and in compliance with the trial results, but only 18% (24/136) commented on both benefits and harms of the trial therapies in the “conclusions” section. Kappa estimates for reporting “conclusions” items ranged from 0.67 to 0.94.

Journal characteristics associated with quality of reporting

The multivariate analysis (see Table 3) only demonstrated an effective word count limitation (>250 vs ≤250) as being significantly associated with a better reporting of abstracts (Incidence Rate Ratio (IRR) 1.152, 95% CI 1.010; 1.314). The multiple Poisson regression’s model fit was estimated 15 % (*Nagelkerk’s Pseudo R²*). Abstracts with an effective word count of > 250 achieved median 9 fulfilled items, abstracts with ≤ 250 words a median of 8 items. In contrast, journals with IF> 3 and journals with IF<3 showed no difference in median fulfillment (8 items both).

Table 3

Results of multivariate analysis (multiple Poisson regression) relating the total number of reported abstract items among 16 CONSORT recommendations per considered RCT publications (n=136) to general characteristics of the underlying journals; associations between violation counts and journal characteristics were quantified via Incidence Rate Ratios (IRR) point estimates and the corresponding un-adjusted two-sided 95% confidence intervals (CI lower and upper bound, respectively); un-adjusted two-sided p-values were derived from Likelihood Ratio tests and indicate locally significant associations in case of p≤ 0.05.

	IRR	95% CI lower	95% CI upper	p-value
publication date [<2008 / ≥2008]	1.111	0.981	1.258	0.098

journal impact factor [publication year]	1.002	0.994	1.009	0.645
trial design multicentric [yes / no]	1.071	0.923	1.243	0.645
structured abstract [yes / no]	1.078	0.833	1.400	0.567
effective sample size [<100 / ≥ 100]	1.053	0.906	1.223	0.567
word count limitation [≤250 / >250]	1.152	1.010	1.314	0.035

DISCUSSION

In the present study, 136 RCT abstracts concerning the treatment of AMD were identified and assessed. The overall quality of reporting based on the CONSORT for abstracts checklist criteria was with median 7 reported items out of 16 items suboptimal. Only two CONSORT items (“interventions” and “objectives”) were adequately reported in most abstracts (> 90%). However, no abstract provided complete information on outcomes as required. The main problem was found in the reporting of effect size and confidence interval (for each trial arm / group as well as in total). Less than 25% of abstracts included sufficiently reported “recruitment”, “numbers analysed”, “conclusions”, “trial registration” and “funding”. Information on “randomisation” was available in 29% which also implies that reporting was not transparent. In the conclusions section most abstracts (96%) reported conclusions consistent with the results but just a few of them (18%) addressed potential limitations of the study or noted whether additional studies were required due to different reasons.

In particular, none of the 136 abstracts presented sufficient reporting of result outcomes, which demonstrates the crucial need for improvement in this field by, for example, provision of explicit instructions for authors in terms of standard reporting formats. The non-reporting of the effect size and its confidence interval for primary outcome has to be identified as the main problem.

Two further studies of Hua (0% pre- and 2.3% post-CONSORT)[21] and Chen (1%)[10] presented similar results. Other studies showed better but also improvable reporting of outcomes (Bigna 25.2% pre and 42.5% post[3]; Can 5.6-18.4% pre and 20.4-38.8% post, depending on the journal[16]; Berwanger 62.3 % [11]). From our point of view, the abstract is crucial, and therefore the outcomes are essential in an abstract. Strict fulfilment of all criteria

1
2
3 as indicated by the CONSORT Statement for abstracts was therefore required by the
4 authors: primary outcome result for each group and for primary outcome as well as effect
5 size and confidence interval (CI) reported appropriate for trials with binary outcome resp. with
6 continuous outcome. In this respect, we have not allowed any scope for interpretation and
7 the parallel reader evaluation followed a strict “no tolerance strategy”, which might explain
8 the embarrassing result for this item in our investigation. In addition, in a randomised study
9 with at least two different therapies, it should be possible to present an effect size between
10 them.
11
12
13
14

15 Age-related macular degeneration is a common eye disease with an increasing need for
16 research in the last years. However, the reporting quality of RCT abstracts concerning AMD
17 therapy has not been assessed until we conducted our study. Our findings were disillusioning
18 but consistent with previous studies assessing the quality of reporting of journal RCT
19 abstracts concerning different diseases: Bigna[3], for example, found in 2016 in 312
20 abstracts concerning HIV median 6 reported items pre-CONSORT and median 7 items post-
21 CONSORT, and stated that this suboptimal improvement was associated with the journal’s
22 high impact factor, large number of authors and non-pharmacological/vaccine intervention in
23 the trial. Also in 2016, Chhapola found in 891 abstracts in three leading paediatrics
24 journals[18] median 7 to 8 items (depending on the journal) pre-CONSORT and median 7 to
25 10 items post-CONSORT. The authors assumed that the reporting quality may be affected
26 by constraints of space and word limit as well as structured vs. unstructured abstracts.
27 Ghimire[23] investigated 956 phase III oncology trial abstracts published pre- and post-
28 CONSORT for abstracts and found median 8.2 (95% CI 8.0, 8.3) and 9.9 (95% CI: 9.7, 10.2)
29 in the pre- and post-CONSORT periods, respectively. A high impact factor and the journal of
30 publication were independent factors significantly associated with higher reporting quality on
31 their multivariate analysis. In our study, the multivariate analysis showed that only the
32 effective number of words had an influence on the quality of abstracts. Hopewell[5] showed
33 that with a word limit of 250 to 300 words the checklist items could be easily incorporated.
34 This was also reflected in our investigation: Abstracts with > 250 words showed better
35 reporting than abstracts with 250 words or less. It is conceivable that with a word limit of
36 maximum 250 words medical authors focus on medical aspects and less on methodological
37 aspects such as randomisation, blindness, trial status, or a correct outcome presentation as
38 recommended by CONSORT. On the other hand, Berwanger 2009[11] impressively
39 demonstrated the possibility of expressing maximum information about methodological
40 aspects in just a few words.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 In this study, the impact factor of journals or structuring of abstracts did not affect the quality
55 of reporting in AMD abstracts as was found in other studies. One reason for this could be the
56
57
58

1
2
3 inclusion of 36 different journals, in which RCTs concerning AMD were published between
4 2004 and 2013. We had determined the impact factor (IF) for each journal depending on the
5 year of publication: Therefore, we had a great variability in the impact factors ranging from 0
6 to 52.414 and a median IF of 3.125. Most other studies relate to abstracts in pre-selected
7 journals[11, 16, 10, 18, 12, 14, 17] specialised in the particular disease. These studies refer
8 to a handful of pre-selected journals with only a few different IFs, which possibly explains this
9 influence in contrast to our study. Furthermore, only eight journals with nine abstracts
10 contained unstructured abstracts in this investigation. This could be the reason why an
11 influence of abstract structure was not demonstrated here. The present investigation also
12 failed to demonstrate an improvement of quality after publication of the CONSORT extension
13 for abstracts in 2008. This result is similar to several previous surveys[26, 19, 20, 18],
14 whereas some other studies using a simple pre-post comparison showed a slight
15 improvement[16, 23, 14, 3]. Due to the inclusion of all journals without pre-selection and over
16 a long period of publication, the authors were not able to identify whether the respective
17 journal made a reference to the CONSORT Statement at the publication time of each RCT,
18 and especially whether the journal contained a reference to the CONSORT extension for
19 abstracts. This is certainly a limitation of this investigation which, however, was not
20 preventable due to a lack of (online) information.
21
22
23
24
25
26
27
28
29

30 Our study shows high process validity from the methodological perspective, as the
31 identification of RCTs, eligibility decision and data extraction were performed by two
32 independent readers, both having several years of experience in the publication and
33 reviewing of clinical trials. In addition, all items were clearly parameterised before the
34 investigation by means of a standard operation procedure on the CONSORT items'
35 evaluation, and then discussed and mutually validated by means of these procedures. For
36 this purpose, a pilot study in a different indication (cataract surgery) was carried out[25] in
37 order to identify possible weaknesses and interferences in advance. Nevertheless, kappa
38 values for some items only showed moderate inter-observer reliability. This is partly
39 explained by the fact that it was difficult – based only on the written information – to decide
40 whether abstracts contained information on “numbers randomised” or “numbers analysed”.
41 Only in a few cases both information were presented explicitly. Therefore, the “moderate”
42 inter-observer reliability in these items was not only based on different ratings, but also on
43 non-transparent and unclear reporting in the respective abstract.
44
45
46
47
48
49
50

51 The use of a sensitive PubMed research strategy and the data collection from 2004 to 2013
52 led to the inclusion of all published RCTs in AMD with no selection of special journals. This
53 represents the whole body of scientific evidence in the field of age-related macular
54
55
56
57
58
59
60

1
2
3 degeneration. We did not take a random sample of RCTs due to the already manageable
4 number of published abstracts.
5

6
7 An undeniable limitation is that both readers were not blinded to the journal and publication
8 period so the possibility of assessor bias cannot be ruled out entirely. Furthermore, as in
9 other studies[11, 3, 16, 10, 18, 14, 17], all 16 CONSORT items were equally weighted and
10 only the presence of an item was rated as “yes / no”. However, it can be noted that certainly
11 not all items have the same impact on the transparency of the reporting process, and some
12 items, e.g. on explicit result presentation, are certainly be more important than others such
13 as details on funding. Nevertheless, all items of the CONSORT checklist should be reported
14 in an abstract and a median number of reported items of 7 (95% CI 7; 8) must be considered
15 as suboptimal reporting quality.
16
17
18
19

20
21 In summary, the reporting quality of RCT abstracts on AMD health care showed a
22 considerable potential for improvement to meet the CONSORT abstract reporting
23 recommendations. Knowledge of the reporting guidelines and CONSORT checklist should be
24 mandatory for both authors and reviewers. The author instructions of ophthalmological
25 journals should consider to explicitly refer to the CONSORT Statement for abstracts in order
26 to ensure transparent reporting. Furthermore, word count limits for abstracts of 250 were
27 identified as a significant determinant of the overall abstract reporting quality.
28
29
30
31
32
33
34
35

36 REFERENCES

- 37
38 1 Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and
39 the hierarchy of research designs. *N Engl J Med* 2000;342:1887-
40 92.doi:10.1056/NEJM200006223422507.
41 2 Stolberg HO, Norman G, Trop I. Randomized controlled trials. *AJR Am J Roentgenol*
42 2004;183:1539-44.doi:10.2214/ajr.183.6.01831539.
43 3 Bigna JJ, Noubiap JJ, Asangbeh SL, et al. Abstracts reporting of HIV/AIDS randomized
44 controlled trials in general medicine and infectious diseases journals: completeness to date
45 and improvement in the quality since CONSORT extension for abstracts. *BMC Med Res*
46 *Methodol* 2016;16:138.doi:10.1186/s12874-016-0243-y.
47 4 The impact of open access upon public health. *PLoS Med*
48 2006;3:e252.doi:10.1371/journal.pmed.0030252.
49 5 Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials
50 in journal and conference abstracts: explanation and elaboration. *PLoS Med*
51 2008;5:e20.doi:10.1371/journal.pmed.0050020.
52 6 Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized
53 controlled trials. The CONSORT statement. *JAMA* 1996;276:637-9
54 7 Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised
55 recommendations for improving the quality of reports of parallel group randomized trials.
56 *BMC Med Res Methodol* 2001;1:2
57
58
59

- 1
2
3 8 Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration:
4 updated guidelines for reporting parallel group randomised trials. *BMJ*
5 2010;340:c869.doi:10.1136/bmj.c869.
6 9 Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for
7 reporting parallel group randomised trials. *Trials* 2010;11:32.doi:10.1186/1745-6215-11-32.
8 10 Chen Y, Li J, Ai C, et al. Assessment of the quality of reporting in abstracts of randomized
9 controlled trials published in five leading Chinese medical journals. *PLoS One*
10 2010;5:e11926.doi:10.1371/journal.pone.0011926.
11 11 Berwanger O, Ribeiro RA, Finkelsztejn A, et al. The quality of reporting of trial abstracts is
12 suboptimal: survey of major general medical journals. *J Clin Epidemiol* 2009;62:387-
13 92.doi:10.1016/j.jclinepi.2008.05.013.
14 12 Ghimire S, Kyung E, Kang W, et al. Assessment of adherence to the CONSORT
15 statement for quality of reports on randomized controlled trial abstracts from four high-impact
16 general medical journals. *Trials* 2012;13:77.doi:10.1186/1745-6215-13-77.
17 13 Knobloch K, Vogt PM. Adherence to CONSORT abstract reporting suggestions in surgical
18 randomized-controlled trials published in *Annals of Surgery*. *Ann Surg* 2011;254:546; author
19 reply -7.doi:10.1097/SLA.0b013e31822ad829.
20 14 Mbuagbaw L, Thabane M, Vanniyasingam T, et al. Improvement in the quality of abstracts
21 in major clinical journals since CONSORT extension for abstracts: a systematic review.
22 *Contemp Clin Trials* 2014;38:245-50.doi:10.1016/j.cct.2014.05.012.
23 15 Samaan Z, Mbuagbaw L, Kosa D, et al. A systematic scoping review of adherence to
24 reporting guidelines in health care literature. *J Multidiscip Healthc* 2013;6:169-
25 88.doi:10.2147/JMDH.S43952.
26 16 Can OS, Yilmaz AA, Hasdogan M, et al. Has the quality of abstracts for randomised
27 controlled trials improved since the release of Consolidated Standards of Reporting Trial
28 guideline for abstract reporting? A survey of four high-profile anaesthesia journals. *Eur J*
29 *Anaesthesiol* 2011;28:485-92.doi:10.1097/EJA.0b013e32833fb96f.
30 17 Wang L, Li Y, Li J, et al. Quality of reporting of trial abstracts needs to be improved: using
31 the CONSORT for abstracts to assess the four leading Chinese medical journals of
32 traditional Chinese medicine. *Trials* 2010;11:75.doi:10.1186/1745-6215-11-75.
33 18 Chhapola V, Tiwari S, Brar R, et al. An interrupted time series analysis showed
34 suboptimal improvement in reporting quality of trial abstract. *J Clin Epidemiol* 2016;71:11-
35 7.doi:10.1016/j.jclinepi.2015.10.013.
36 19 Kiriakou J, Pandis N, Madianos P, et al. Assessing the reporting quality in abstracts of
37 randomized controlled trials in leading journals of oral implantology. *J Evid Based Dent Pract*
38 2014;14:9-15.doi:10.1016/j.jebdp.2013.10.018.
39 20 Seehra J, Wright NS, Polychronopoulou A, et al. Reporting quality of abstracts of
40 randomized controlled trials published in dental specialty journals. *J Evid Based Dent Pract*
41 2013;13:1-8.doi:10.1016/j.jebdp.2012.11.001.
42 21 Hua F, Walsh T, Glenny AM, et al. Reporting quality of randomized controlled trial
43 abstracts presented at European Orthodontic Society congresses. *Eur J Orthod*
44 2016;38:584-92.doi:10.1093/ejo/cjv094.
45 22 Faggion CM, Jr., Giannakopoulos NN. Quality of reporting in abstracts of randomized
46 controlled trials published in leading journals of periodontology and implant dentistry: a
47 survey. *J Periodontol* 2012;83:1251-6.doi:10.1902/jop.2012.110609.
48 23 Ghimire S, Kyung E, Lee H, et al. Oncology trial abstracts showed suboptimal
49 improvement in reporting: a comparative before-and-after evaluation using CONSORT for
50 Abstract guidelines. *J Clin Epidemiol* 2014;67:658-66.doi:10.1016/j.jclinepi.2013.10.012.
51 24 Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal
52 neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report
53 no. 13. *Ophthalmology* 2004;111:1993-2006.doi:10.1016/j.ophtha.2004.07.023.
54 25 Baulig C, Krummenauer F, Knippschild S. [Evaluation of methodological quality in
55 published RCTs on cataract surgery : Pilot study on the degree of adherence to CONSORT
56 statement requirements and their qualitative validity]. *Ophthalmologie* 2018;115:40-
57 6.doi:10.1007/s00347-017-0446-6.
58
59
60

1
2
3 26 Blair DA, Hughes PJ, Woolley TW, Jr. Pharmacy journal abstracts published in PubMed
4 that abide by the CONSolidated Standards Of Reporting Trials (CONSORT) guidelines. *J*
5 *Med Libr Assoc* 2014;102:110-4.doi:10.3163/1536-5050.102.2.010.
6
7
8
9

10 **Acknowledgment**

11
12 The authors would like to thank Mrs. Manuela Munk for linguistic support in preparing this
13 manuscript.
14

15 **Funding**

16
17
18 The authors are grateful to the Internal Research Foundation Initiative of the Witten /
19 Herdecke University's Faculty of Health, which enabled this investigation by means of a
20 supportive research grant comprising a one-year research position for Dr. Stephanie
21 Knippschild.
22
23
24
25
26

27 **Authors' Contributions**


28
29 Grant application: CB, SK, FK. Study conception and design: CB, SK, FK. Data collection:
30 CB, SK. Abstract selection: CB, SK. Data extraction: CB; SK. Statistical analysis: FK, BG,
31 ST. Data interpretation: CB, SK, FK, BG, ST. Drafting: CB. Critical discussion and
32 manuscript revision: FK, SK. Approval of final version: All authors.
33
34
35
36
37

38 **Data sharing statement**

39
40 The data may be obtained from the authors for academic purposes.
41
42
43
44

45 Figure 1:

46
47 Flowchart of the literature search and identification of randomized controlled clinical trial
48 abstracts
49
50
51
52
53
54
55
56
57
58
59
60



Flowchart of the literature search and identification of randomized controlled clinical trial abstracts

81x60mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	3
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	--
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	--
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	--
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19/3

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Reporting Quality of Randomised Controlled Trial Abstracts on Age-Related Macular Degeneration Health Care – A Cross Sectional Quantification of the Adherence to CONSORT Abstract Reporting Recommendations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021912.R1
Article Type:	Research
Date Submitted by the Author:	12-Mar-2018
Complete List of Authors:	Baulig, Christine; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Krummenauer, Frank; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Geis, Berit; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Tulka, Sabrina; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University , Department of Medicine Knippschild, Stephanie; Institute for Medical Biometry and Epidemiology, Witten/Herdecke University, Departement of Medicine
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Epidemiology
Keywords:	reporting quality, Abstract, randomized controlled trial, CONSORT, age related macula degeneration

SCHOLARONE™
Manuscripts

1
2
3 **Reporting quality of Randomised Controlled Trial Abstracts on Age-Related Macular**
4 **Degeneration Health Care – A Cross Sectional Quantification of the Adherence to**
5 **CONSORT Abstract Reporting Recommendations**
6
7

8
9 Christine Baulig, Frank Krummenauer, Berit Geis, Sabrina Tulka, Stephanie Knippschild
10

11
12 Corresponding author:

13 JProf Christine Baulig MSc
14 Institute for Medical Biometry and Epidemiology
15 Faculty of Health, Witten/Herdecke University
16 Alfred-Herrhausen-Straße 50
17 58448 Witten, Germany
18 Phone: +49 (0)2302 926 782
19 E-mail: Christine.Baulig@uni-wh.de
20
21

22
23 Co-Authors:

24
25 Prof Dr Frank Krummenauer
26 Institute for Medical Biometry and Epidemiology
27 Faculty of Health, Witten/Herdecke University
28 Alfred-Herrhausen-Straße 50
29 58448 Witten, Germany
30

31 MSc Berit Geis
32 Institute for Medical Biometry and Epidemiology
33 Faculty of Health, Witten/Herdecke University
34 Alfred-Herrhausen-Straße 50
35 58448 Witten, Germany
36
37

38 MSc Sabrina Tulka
39 Institute for Medical Biometry and Epidemiology
40 Faculty of Health, Witten/Herdecke University
41 Alfred-Herrhausen-Straße 50
42 58448 Witten, Germany
43

44 Dr Stephanie Knippschild
45 Institute for Medical Biometry and Epidemiology
46 Faculty of Health, Witten/Herdecke University
47 Alfred-Herrhausen-Straße 50
48 58448 Witten, Germany
49
50

51
52
53 **Word count: 4.154**
54
55
56
57
58
59
60

1
2
3 Objective: To assess the reporting quality of RCT abstracts on AMD health care, to evaluate
4 the adherence to the CONSORT statement's recommendations on minimum abstract
5 information and to identify journal characteristics associated with abstract reporting quality.
6
7

8 Design: Cross-sectional evaluation of RCT abstracts on AMD health care
9

10 Methods: A PubMed search was implemented to identify RCT abstracts on AMD health care
11 published in English language between 01/2004 and 12/2013. Data extraction was
12 performed by two parallel readers independently by means of a documentation format in
13 accordance with the 16 items of the CONSORT checklist for abstracts. The total number of
14 criteria fulfilled by an abstract was derived as primary endpoint of the investigation, incidence
15 rate ratios (IRRs) with un-adjusted 95% confidence intervals (95% CI) were estimated by
16 means of multiple Poisson regression to identify journal and article characteristics
17 (publication year, multicentre design, structured abstract recommendations, effective sample
18 size, effective abstract word counts and journal impact factor) possibly associated with the
19 total number of fulfilled items.
20
21
22
23
24

25 Study characteristics: 136 of 673 identified abstracts (published in 36 different journals)
26 fulfilled all eligibility criteria.
27
28

29 Results: The median number of fulfilled items was 7 (95% CI 7; 8). No abstract reported all
30 16 recommended items; the maximum total number was 14, the minimum 3 of 16 items.
31 Multivariate analysis only demonstrated the abstracts' word counts as being significantly
32 associated with a better reporting of abstracts (Poisson regression based Incidence Rate
33 Ratio 1.002, 95% CI 1.001; 1.003).
34
35
36
37

38 Conclusions: Reporting quality of RCT abstracts on AMD investigations showed a
39 considerable potential for improvement to meet the CONSORT abstract reporting
40 recommendations. Furthermore, word counts of abstracts were identified as significantly
41 associated with the overall abstract reporting quality.
42
43

44 Key Words: RCT, structured abstract, CONSORT statement, reporting quality
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Reporting quality of RCT abstracts on AMD therapy has not been assessed so far.
- The cross-sectional inclusion of all published RCT abstracts on AMD health care without selection of journals ensures maximum possible representativeness.
- Data extraction and evaluation were performed by two independent readers with long-term experience in clinical trial methodology and reporting bias evaluation.

- The readers were not blinded to the journal and publication period, so that the possibility of reader bias cannot be ruled out entirely.
- Journal characteristics could only be considered as far as published by the journals; the individual reviewing processes underlying the 136 abstracts might have taken additional influence on the actual abstract presentations.

Funding: This work was supported by the Internal Research Foundation Initiative of the Witten / Herdecke University's Faculty of Health, comprising a one-year research position for SK (grant number IFF 2016-001).

Competing interests

The authors declare that they have no competing interests. From the perspective of Good Scientific Practice the authors state, that parts of this manuscript will be presented orally and by means of a congress abstract to be submitted to the 2018 annual meeting of the German Ophthalmic Surgeons (DOC congress, Nuremberg, June 2018).

INTRODUCTION

Randomised controlled trials (RCT) are considered as optimum origin of evidence and have the highest grade of research designs[1, 2]. Frequently, readers of articles reporting on RCT start by screening the content of the abstract first, which subsequently guides the decision whether or not to obtain and read the entire article[3]. In addition to an overwhelming day-to-day workload, a steadily increasing number of publications and limited access to many full-text articles enforce health care providers to build their health care decisions on information in abstracts[4]. Thus, abstracts of RCTs should contain accurate and clear information about implementation, evaluation, findings and synopsis of the clinical trial[5].

Regarding the methodological details, there was no standardised reporting requirement before the Consolidated Standards of Reporting Trials (CONSORT) were established in 1996[6] and revised in 2001[7] and 2010[8, 9], respectively. In order to prevent discrepancies between full-text articles and abstracts, as well as to improve the reporting quality of abstracts, an extension to the CONSORT Statement was published in 2008[5]. This statement contains 17 items comprising eight sections: title, authors' details (specific to conference abstracts), trial design, methods (including participants, interventions, objectives, defined primary outcome, randomisation, blinding), results (numbers randomised, recruitment, numbers analysed, outcomes, harms), conclusions, trial registration and declaration of funding[5]. This enumeration "provides a minimum list of essential items, that authors should consider when reporting the main results of a randomized trial in any journal or conference abstract"[5].

Several studies have been conducted to evaluate the quality of abstract reporting in general medical journals[10-14] or specific fields of medicine such as health care[15], anaesthesia[16], traditional Chinese medicine[17], HIV/AIDS[3], paediatrics[18], dentistry[19-22] and oncology[23]. These studies thoroughly demonstrated, that there is still a need for optimisation in the reporting of RCT abstracts.

To our knowledge, the reporting quality of RCT abstracts in the field of ophthalmology and especially regarding the treatment of age-related macular degeneration (AMD) has not been assessed yet. AMD is a common eye disease and the leading cause for vision loss among people 50 years of age and older [24], having led to increasing research need on therapeutic concepts and thereby to an increasing number of RCTs on AMD during the past decade. Therefore, the objectives of the present cross-sectional complete census were to assess the reporting quality of RCT abstracts in AMD health care, to evaluate the adherence to the

1
2
3 CONSORT statement's recommendations on minimum abstract information and to identify
4 journal characteristics associated with this parameterisation of abstract reporting quality.
5
6
7

8 METHODS

9 Study design

10
11
12 A cross-sectional evaluation of RCT abstracts on AMD health care published between 2004
13 and 2013 was implemented; to identify eligible RCT publication abstracts, a systematic
14 review of abstracts was performed without any restrictions (implying a complete census of all
15 published abstracts), according to the PRISMA reporting guidance (see online
16 supplementary material for PRISMA checklist). Human subjects were not involved in this
17 study.
18
19
20
21
22
23

24 Data sources and search strategy

25
26
27 A MEDLINE / PubMed search for all RCTs published between 2004 and 2013 was
28 performed. The search strategy used the MeSH terms "randomised controlled trial" as
29 publication type and "macular degeneration" as term in title / abstract and was limited to the
30 publication date (2004/01/01 to 2013/12/31) as well as to English as publication language.
31 The publication period was limited in order to reflect the period five years before and after the
32 publication of the extension of CONSORT in 2008. The search was carried out on
33 2015/09/24 as can be reproduced by online audit trail documentation (supplementary
34 material).
35
36
37
38
39
40
41

42 Study selection

43
44 Only abstracts reporting on age-related macular degeneration (AMD) health care were
45 considered and then investigated for indications of an underlying RCT design: we included
46 abstracts in which the allocation of participants to interventions was described by the words
47 "random", "randomly", "randomised", "randomisation" or any other terminology suggesting
48 that the participants were randomly distributed to treatment arms. Reports not associated
49 with AMD therapy, without reference to randomisation or an obviously retrospective study
50 design, economic analyses, diagnostic or screening tests, questionnaire reporting, study
51 protocols, observational studies, editorials or letters were excluded as well as reviews, meta-
52 analyses and non-human studies. Two parallel reviewers (CB, SK) independently selected
53
54
55
56
57
58
59
60

1
2
3 the abstracts; disagreement about which abstracts had to be included was resolved by
4 discussion and consensus, reasons for article exclusion were documented.
5

6 Patient and Public involvement 7

8
9 The present work does not include original patient data but is based on the evaluation of
10 published abstracts of RCTs in ophthalmological journals. Therefore no patients or public
11 were involved in this study.
12

13 Data extraction 14

15
16 A pilot study was performed with randomly selected abstracts concerning cataract surgery to
17 identify problems and solve discrepancies in data collection and analysis[25]. The data
18 extraction was performed in the same way (CB, SK) using the previously created and
19 pretested data extraction and documentation form in accordance to the items of the
20 CONSORT checklist for abstracts[5]. Each item had a “yes”/“no” rating indicating whether the
21 authors had reported this item or not. Only the “authors’ details” item concerning contact
22 details of the corresponding authors was excluded from the assessment, since this item is
23 specific to conference abstracts. For the “outcomes” item two sub-items were evaluated – as
24 required by the CONSORT Statement: 1) primary outcome result presented for each group /
25 arm, 2) for primary outcome, effect size reported for trials with binary outcome resp. with
26 continuous outcome and the precision of this effect size (confidence interval (CI)). Only if
27 both criteria were met, a correct reporting of the outcome results items was ascertained. For
28 the “conclusions” item also two sub-items had to be reported: 1) consistency with the
29 reported results and 2) discussion of benefits of and harms from the intervention. Again, only
30 if both sub-items were reported, the correct reporting of “conclusions” was ascertained.
31
32
33
34
35
36
37
38

39 Furthermore, the following information on journal and article characteristics were collected:
40 name of the journal, name of first author, year of publication, multicentre design [yes/no],
41 abstract format pre-specified as structured [yes/no], effective sample size, impact factor of
42 each journal according to the respective publication year. Due to the fact that word count
43 limits in instructions for authors were found to show severe deviations from the number of
44 words actually used in the abstract, both counts were recorded (word count limitation (status
45 2017) as well as actual word count in the abstract). In addition, since only the current word
46 count specifications of each journal could be found (status 2017), the actual word counts for
47 each abstract were used for exploratory evaluations (see below).
48
49
50
51
52
53
54

55 Primary Endpoint 56 57 58 59 60

1
2
3 The abstract-wise primary endpoint of this investigation was the total absolute number of
4 items (among all 16 considered) reported in the respective abstract. To provide maximum
5 scientific evidence we decided to evaluate all existing abstracts (N = 136) and did not draw a
6 random sample, thereby providing a complete census of all available abstracts.
7
8
9

10 11 12 Exploratory Analysis

13
14 Descriptive analysis of the primary endpoint was based on medians and quartiles, graphical
15 presentation on box whisker plots, accordingly. For each CONSORT abstract item Cohen's
16 kappa (point estimate and one-sided 95% confidence interval) were derived to assess the
17 parallel readers' agreement, respectively. A kappa point estimate of 0.60 or higher was
18 considered as an indication for substantial inter-observer agreement in the evaluation of the
19 respective item.
20
21
22
23
24
25

26 27 Multivariate Analysis

28 Incidence rate ratios (IRRs) with 95% confidence intervals (95% CI, not adjusted for
29 multiplicity with regard to the exploratory character of the multivariate analysis) were
30 estimated by means of multiple Poisson regression to identify journal and article
31 characteristics (publication year, multicentre design, structured abstract recommendations,
32 effective sample size, effective abstract word counts and journal impact factor) possibly
33 associated with the total number of fulfilled criteria. Poisson regression modelling was
34 performed by backward variable selection via the AIC criterion, considering Likelihood Ratio
35 test p-values < 0.05 as indicators of local statistical significance (i.e. model exploration
36 results were not formally adjusted for multiplicity). The multivariate analysis was conducted
37 using "R" version 3.4.0 (R Core Team, 2017).
38
39
40
41
42
43
44
45

46 47 RESULTS

48 Out of 673 identified study publications 537 had to be excluded (Figure 1). In summary, a
49 total of 136 abstracts fulfilling the eligibility criteria were included in the investigation.
50
51
52
53

54 55 Characteristics of included abstracts and underlying journals

56
57
58
59
60

The search yielded 136 abstracts of which 55 (40%) were published between 2004 and 2008 (pre-CONSORT) and 81 (n=60%) between 2009 and 2013 (post-CONSORT). The abstracts were published in 36 different journals, of which only two (publishing four articles) had no Thomson & Reuter impact factor. The median impact factor of all journals – according to the respective publication year – was 3.125 (interquartile range Q1 2.367; Q3 5.127). Only seven studies (5%) were published in journals with an impact factor of 10 or higher. Most of the publications (32%) were found in “Ophthalmology” (43/136) followed by “British Journal of Ophthalmology” 10% (13/136) and “Retina” 9% (12/136) (Table 1).

Only one journal did not state word count limits for abstracts in the instructions for authors (status 2017). All other 35 journals limited the words in abstracts to a total number between 200 and 500 words (see Table 1). The actual number of words in abstracts varied between 141 (minimum) and 457 (maximum) with a median of 273 words. 70 (51%) studies were single-centre trials with a minimum sample size of 7 participants up to 300 participants (median 46, Q1 28; Q3 100), and 66 (49%) studies were multi-centre trials with a minimum sample size of 25 participants up to 2457 participants (median 223, Q1 117; Q3 494).

Table 1

Listings of journals with at least one AMD RCT abstract considered in the evaluation, total number of publications (N) with abstracts evaluation from the respective journal as well as relative frequency [%] of these abstracts among all abstracts considered in this investigation, 5-years impact factor (Thomson & Reuter, 2016), as well as information on word count limits according to the published instructions for authors of the respective journals (status 2017).

Journal <i>(Journal Title Abbreviation)</i>	N	proportion <i>(%)</i>	5-years IF <i>(2016)</i>	word count limits <i>(words)</i>
Am J Ophthalmol	9	7	4.797	250
Ophthalmology	43	32	7.788	350
Graefes Arch Clin Exp Ophthalmol	4	3	2.274	250
Br J Nutr	1	1	3.784	250
Clin Hemorheol Microcirc	1	1	1.647	200
Atheroscler Suppl	1	1	3.310	250
N Engl J Med	4	3	64.201	250
Retina	12	9	3.779	200
Arch Ophthalmol	5	4	4.372	350
Br J Ophthalmol	13	10	3.466	250

1					
2					
3	Scand J Occup Ther	1	1	1.561	200
4	Acta Ophthalmologica	7	5	2.812	250
5	Eye (Lond)	5	4	2.547	250
6	Nutrients	1	1	4.187	200
7	PLoS One	1	1	3.394	300
8	Nutrition	2	2	3.312	250
9	Curr Med Res Opin	1	1	2.605	250
10	Invest Ophthalmol Vis Sci	4	3	3.786	250
11	Clin Rehabil	1	1	3.026	250
12	Trans Am Ophthalmol Soc	1	1	0.000	250
13	Optometry	3	2	0.000	250
14	Biomedical Papers	1	1	1.160	250
15	J Clin Neurosci	1	1	1.545	250
16	BMJ	1	1	19.355	
17	Proc Natl Acad Sci U S A	1	1	10.414	250
18	JAMA Ophthalmol	1	1	5.425	350
19	Eur J Ophthalmol	1	1	1.161	250
20	Complementary and Alternative Medicines	1	1	2.644	300
21	BMC Ophthalmology	1	1	1.579	350
22	Experimental Eye Research	2	2	3.235	500
23	Current Eye Research	2	2	1.947	300
24	Annals of Nutrition and Metabolism	1	1	2.883	250
25	Lancet	1	1	48.082	300
26	Ophthalmologica	1	1	1.918	250
27	J Ocul Pharmacol Ther	1	1	1.726	250
28	Total	136			
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

Overall reporting quality

None of the 136 abstracts reported all 16 items. The best abstract reported 14 of 16, the worst 3 of 16 items. The median number of reported items was 7 (95% CI 7; 8). Comparing the pre- and post-CONSORT periods, abstract reporting improved from median 7 (95% CI 6; 7) to median 8 (95% CI 7; 8) reported items. In total, 104 of 136 abstracts (77%) reported 8 items or less, whereas 32 abstracts stated 9 items or more (23%). Best reported items were “interventions” (95% reported) and “objectives” (98%). The worst reporting was on “outcomes” with 0% (see Table S, supplementary material).

Reporting of “general items”

Only 42% (57/136) identified the presented investigation as randomised in the title. 71% (97/136) described the trial design as required (the information “randomised controlled trial” or “multi-centre / single-centre” were not sufficient).

Reporting of “trial methodology”

Eligibility criteria for participants and for interventions – to be documented for each treatment group – were reported in 90% (123/136) and 95% (129/136), respectively. Similarly, the specific objective or hypothesis was mentioned in 98% (133/136). 70% (95/136) reported a clearly defined primary outcome. Only 29% (39/136) of abstracts stated information on randomisation and 43% (59/136) on blinding. Details about trial status were given in 9% (12/136).

Reporting of “results”

Of the 136 abstracts included, 55% (75/136) reported the number of participants randomised to each group, but only 22% (30/136) reported the number of participants analysed for each group. Important adverse events were described in 48% (65/136). As CONSORT recommends three different sub-items for reporting outcomes, this investigation found a total of 64% (87/136) abstracts reporting primary outcome results for each group, but none of the 136 abstracts reported on effect size and confidence interval for the primary outcome in full detail. The proportion of abstracts describing effect size and confidence intervals for primary outcome was 7% (9/136), among which 7% (3 out of 41 trials) with binary outcome and 6% (6 out of 95 trials) with continuous outcome. In total, none of the 136 abstracts met both criteria, so the correct reporting frequency for the “results” indicators was estimated 0%.

Reporting of “conclusions”

Information on a trial registration number was found in 19% (26/136) of the abstract, and a possible funding source was referenced in 24% (33/136). Correct interpretations of the results in the “conclusions” section as recommended by CONSORT were available in 17% (23/136): 96 % (130/136) of the abstracts reported adequately and in compliance with the trial results, but only 18% (24/136) commented on both benefits and harms of the trial therapies in the “conclusions” section.

Agreement among parallel readers

Table 2 shows the inter-observer agreement for each item [Cohen's kappa and one-sided 95% confidence intervals]. Substantial agreement was found for almost all items under consideration. Notable less in agreement as indicated by kappa point estimates < 0.6 were only found for the items “randomisation”, “numbers randomised” and “recruitment”.

Table 2

Item-wise inter-observer agreement [Cohen's kappa, asymptotic one-sided 95% confidence intervals] for 16 abstract reporting items as recommended by the CONSORT statement: kappa point estimates > 0.60 were considered as indicators of substantial parallel reader agreement

item	Kappa point and one-sided 95% confidence interval estimates for inter-observer agreement	Kappa > 0.60 (substantial agreement)
title	0.91; ≥ 0.84	*
authors *	-	
trial design	0.89; ≥ 0.81	*
Methods		
participants	0.76; ≥ 0.58	*
interventions	0.79; ≥ 0.56	*
objectives	0.74; ≥ 0.40	*
definition of primary outcome	0.63; ≥ 0.49	*
randomisation	0.55; ≥ 0.42	
blinding (masking)	0.81; ≥ 0.71	*
Results		
numbers randomised	0.56; ≥ 0.42	
recruitment	0.51; ≥ 0.24	
numbers analysed	0.65; ≥ 0.51	*
outcomes	1.00; ≥ 0.99	*
harms	0.85; ≥ 0.76	*
conclusions	0.69; ≥ 0.54	*
trial registration	0.84; ≥ 0.72	*
funding	0.94; ≥ 0.87	*

Journal characteristics associated with quality of reporting

The multivariate analysis (see Table 3) only demonstrated the abstracts' effective word counts as being significantly associated with a better reporting of abstracts (Incidence Rate Ratio (IRR) 1.002, 95% CI 1.001; 1.003). As could be expected, the latter indicates a proportional benefit of abstracts with increasing abstract text length. The multiple Poisson

1
2
3 regression's model fit was, however, estimated only 11 % (*Nagelkerk's Pseudo R²*) even
4 after extensive exploratory sensitivity analyses (introducing interaction terms for the
5 explanatory variables under consideration as well as introducing these variables as
6 continuous and binary into the models, respectively).
7
8
9

10
11 **Table 3**

12
13 Results of multivariate analysis (multiple Poisson regression) relating the total number of
14 reported abstract items among 16 CONSORT recommendations per considered RCT
15 publications (n=136) to general characteristics of the underlying journals; associations
16 between violation counts and journal characteristics were quantified via Incidence Rate
17 Ratios (IRR) point estimates and the corresponding un-adjusted two-sided 95% confidence
18 intervals (CI lower and upper bound, respectively); un-adjusted two-sided p-values were
19 derived from Likelihood Ratio tests and indicate locally significant associations in case of $p \leq$
20 0.05.
21
22
23

	IRR	95% CI lower	95% CI upper	p-value
(Intercept)	4.318	3.254	5.730	< 0.001
publication date [<2008 / ≥2008]	1.109	0.975	1.261	0.115
abstract word count	1.002	1.001	1.003	0.001

24
25
26
27
28
29
30
31
32
33 AIC: 587.27

34 35 36 37 DISCUSSION

38
39 In the present study, 136 RCT abstracts concerning the treatment of AMD were identified
40 and assessed. The overall quality of reporting based on the CONSORT for abstracts
41 checklist criteria was with median 7 reported items out of 16 items poor. Only two CONSORT
42 items ("interventions" and "objectives") were adequately reported in most abstracts (> 90%).
43 However, no abstract provided complete information on outcomes as required. The main
44 problem was found in the reporting of effect size and confidence interval (for each trial arm /
45 group as well as in total). Less than 25% of abstracts included sufficiently reported
46 "recruitment", "numbers analysed", "conclusions", "trial registration" and "funding".
47 Information on "randomisation" was available in 29% which also implies that reporting was
48 not transparent. In the conclusions section most abstracts (96%) reported conclusions
49 consistent with the results but just a few of them (18%) addressed potential limitations of the
50 study or noted whether additional studies were required due to different reasons.
51
52
53
54
55
56
57

1
2
3 In particular, none of the 136 abstracts presented sufficient reporting of result outcomes,
4 which demonstrates the crucial need for improvement in this field by, for example, provision
5 of explicit instructions for authors in terms of standard reporting formats. The non-reporting of
6 the effect size and its confidence interval for primary outcome has to be identified as the
7 main problem.
8
9

10
11 Two further studies of Hua (0% pre- and 2.3% post-CONSORT)[21] and Chen (1%)[10]
12 presented similar results. Other studies showed better but also improvable reporting of
13 outcomes (Bigna 25.2% pre and 42.5% post[3]; Can 5.6-18.4% pre and 20.4-38.8% post,
14 depending on the journal[16]; Berwanger 62.3 % [11]). From our point of view, the abstract is
15 crucial, and therefore the outcomes are essential in an abstract. Strict fulfilment of all criteria
16 as indicated by the CONSORT Statement for abstracts was therefore required by the
17 authors: primary outcome result for each group and for primary outcome as well as effect
18 size and confidence interval (CI) reported appropriate for trials with binary outcome resp. with
19 continuous outcome. In this respect, we have not allowed any scope for interpretation and
20 the parallel reader evaluation followed a strict “no tolerance strategy”, which might explain
21 the embarrassing result for this item in our investigation. In addition, in a randomised study
22 with at least two different therapies, it should be possible to present an effect size between
23 them. Randomised controlled trials are expected to provide a high degree of evidence.
24 However, 136 RCT abstracts did not contain sufficiently detailed data on the study outcome
25 (effect size in combination with significance or confidence measure) in such explicit terms as
26 required by the CONSORT statement. This lack of reporting quality certainly means a more
27 crucial loss in transparency and reproducibility than, for example, sub-optimal fulfillment of
28 rather editorial recommendations. In summary, physicians conducting clinical research are
29 strongly advised to involve a biometrician in the formulation of their results.
30
31
32
33
34
35
36
37
38
39

40 Age-related macular degeneration is a common eye disease with an increasing need for
41 research in the last years. However, the reporting quality of RCT abstracts concerning AMD
42 therapy has not been assessed until we conducted our study. Our findings were disillusioning
43 but consistent with previous studies assessing the quality of reporting of journal RCT
44 abstracts concerning different diseases: Bigna[3], for example, found in 2016 in 312
45 abstracts concerning HIV median 6 reported items pre-CONSORT and median 7 items post-
46 CONSORT, and stated that this suboptimal improvement was associated with the journal's
47 high impact factor, large number of authors and non-pharmacological/vaccine intervention in
48 the trial. Also in 2016, Chhapola found in 891 abstracts in three leading paediatrics
49 journals[18] median 7 to 8 items (depending on the journal) pre-CONSORT and median 7 to
50 10 items post-CONSORT. The authors assumed that the reporting quality may be affected
51 by constraints of space and word limit as well as structured vs. unstructured abstracts.
52
53
54
55
56
57
58
59
60

1
2
3 Ghimire[23] investigated 956 phase III oncology trial abstracts published pre- and post-
4 CONSORT for abstracts and found median 8.2 (95% CI 8.0, 8.3) and 9.9 (95% CI: 9.7, 10.2)
5 in the pre- and post-CONSORT periods, respectively. A high impact factor and the journal of
6 publication were independent factors significantly associated with higher reporting quality on
7 their multivariate analysis. In our study, the multivariate analysis showed that only the
8 effective number of words had an influence on the quality of abstracts. Hopewell[5] showed
9 that with a word limit of 250 to 300 words the checklist items could be easily incorporated.
10 This was also reflected in our investigation: Abstracts with > 250 words showed better
11 reporting than abstracts with 250 words or less. It is conceivable that with a word limit of
12 maximum 250 words medical authors focus on medical aspects and less on methodological
13 aspects such as randomisation, blindness, trial status, or a correct outcome presentation as
14 recommended by CONSORT. On the other hand, Berwanger 2009[11] impressively
15 demonstrated the possibility of expressing maximum information about methodological
16 aspects in just a few words.
17
18

19
20
21
22
23
24 In this study, the impact factor of journals or structuring of abstracts was not found
25 associated with the quality of reporting in AMD abstracts as was found in other studies. One
26 reason for this could be the inclusion of 36 different journals, in which RCTs concerning AMD
27 were published between 2004 and 2013. We had determined the impact factor (IF) for each
28 journal depending on the year of publication: Therefore, we had a great variability in the
29 impact factors ranging from 0 to 52.414 and a median IF of 3.125. Most other studies relate
30 to abstracts in pre-selected journals[11, 16, 10, 18, 12, 14, 17] specialised in the particular
31 disease. These studies refer to a handful of pre-selected journals with only a few different
32 IFs, which possibly explains this influence in contrast to our study. Furthermore, only eight
33 journals with nine abstracts contained unstructured abstracts in this investigation. This could
34 be the reason why an influence of abstract structure was not demonstrated here. The
35 present investigation also failed to demonstrate an improvement of quality after publication of
36 the CONSORT extension for abstracts in 2008. This result is similar to several previous
37 surveys[26, 19, 20, 18], whereas some other studies using a simple pre-post comparison
38 showed a slight improvement[16, 23, 14, 3]. Due to the inclusion of all journals without pre-
39 selection and over a long period of publication, the authors were not able to identify whether
40 the respective journal made a reference to the CONSORT Statement at the publication time
41 of each RCT, and especially whether the journal contained a reference to the CONSORT
42 extension for abstracts. This is certainly a limitation of this investigation which, however, was
43 not preventable due to a lack of (online) information.
44
45
46
47
48
49
50
51
52
53

54
55 Our investigation shows high process validity from the methodological perspective, as the
56 identification of RCTs, eligibility decision and data extraction were performed by two
57
58

1
2
3 independent readers, both having several years of experience in the publication and review
4 of clinical trials. In addition, all items were clearly parameterised before the investigation by
5 means of a standard operation procedure on the CONSORT items' evaluation, and then
6 discussed and mutually validated by means of these procedures. For this purpose, a pilot
7 study in a different indication (cataract surgery) was carried out[25] in order to identify
8 possible weaknesses and interferences in advance. Nevertheless, kappa values for some
9 items only showed moderate inter-observer reliability. This is partly explained by the fact that
10 it was difficult – based only on the written information – to decide whether abstracts
11 contained information on “numbers randomised” or “numbers analysed”. Only in a few cases
12 both information were presented explicitly. Therefore, the “moderate” inter-observer reliability
13 in these items was not only based on different ratings, but also on non-transparent and
14 unclear reporting in the respective abstract.
15
16
17
18
19
20

21 We did not take a random sample of RCTs, but rather used systematic review methodology
22 to identify eligible RCT publication abstracts for our purpose, and then decided to perform a
23 full cross-sectional census evaluation on these abstracts. The use of a sensitive PubMed
24 research strategy and the data collection from 2004 to 2013 led to the inclusion of all
25 published RCTs in AMD with no selection of special journals. This represents the whole body
26 of scientific evidence in the field of age-related macular degeneration until the end of the
27 publishing period under consideration – and actually, as we presume – until today. Of course
28 we are aware that the limitation of publication period (2004 – 2013) must be viewed critically:
29 We sought to depict a ten-year period in our study, which covered both the period before and
30 after the publication date of the CONSORT guidelines for abstracts (“CONSORT for
31 abstracts” was published in January 2008[5]). Since we assumed that these
32 recommendations did not find immediate uptake in the year of publication, we defined 2004 -
33 2008 as a 5 years pre-CONSORT and 2009 - 2013 as a sufficiently long-term post-
34 CONSORT 5 years period. It must be admitted, that even after a sufficient uptake time after
35 the “CONSORT for abstracts” being published, the publication date is only a proxy for the
36 actual uptake of the recommendation. For example a publication firstly submitted in 2007 –
37 thereby not underlying the recommendations' content – might have been published in 2009
38 after a two years review and editing process. As a consequence, a 2009 “post-CONSORT”
39 publication would have been miss-classified as actually being written in the pre-CONSORT
40 period. However, during the literature research on this topic we found that various authors
41 had already examined the pre-post comparison [3, 18, 21, 14]. For this reason we included
42 the 2008 cut-point via the binary variable “publication date before / after 2008” in the Poisson
43 regression model. Consequently, the pre-post comparison was thought to be a possible
44 factor influencing the quality of the abstracts. This, however, was not confirmed, which could
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

possibly be due to the selected time periods. A further investigation covering the next five-year period (2014-2018) could possibly show a trend towards CONSORT uptake.

An undeniable limitation is that both readers were not blinded to the journal and publication period so the possibility of assessor bias cannot be ruled out entirely. Furthermore, as in other studies[11, 3, 16, 10, 18, 14, 17], all 16 CONSORT items were equally weighted and only the presence of an item was rated as “yes / no”. However, it can be noted that certainly not all items have the same impact on the transparency of the reporting process, and some items, e.g. on explicit result presentation, are certainly be more important than others such as details on funding. Nevertheless, all items of the CONSORT checklist should be reported in an abstract and a median number of reported items of 7 (95% CI 7; 8) must be considered as poor reporting quality.

A further limitation is that this study was carried out without preparing a study protocol in advance, as its evaluation was based on the previously tried and tested procedure of the pilot study.[25] Nevertheless, there remains a risk of selective reporting.

In summary, the reporting quality of RCT abstracts on AMD health care showed a considerable potential for improvement to meet the CONSORT abstract reporting recommendations. The reporting of the outcomes in particular was disillusioning, even though CONSORT provides detailed information in its checklist explanations on how these results should be presented. Since these further explanations are very detailed, it seems as if these notes are hardly being read, and therefore lack the degree of awareness they deserve. One way to remedy this would be to provide elaborate examples / templates by means of commented "best-practice abstracts" a supplementary material to a journal's "instructions for authors". These abstracts would be held in the authors' terminology and clinical context, and thereby would become much more accessible than easier to imitate for the clinical author than the transfer of recommendation explanations.

Furthermore, word count limits for abstracts of 250 were identified as a significant determinant of the overall abstract reporting quality. These word count limits could possibly be neglected if annotated best-practice abstracts were made available, or else they could be modified according to the requirements of the respective journals in order to improve quality. To reduce the amount of Research-waste[27] improvements in abstract quality are urgently needed. In particular, the correct statement of the exact effect size is of utmost importance in an abstract, in order to be able to transfer a statement into everyday clinical practice.

REFERENCES

- 1 Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 2000;342:1887-92.doi:10.1056/NEJM200006223422507.
- 2 Stolberg HO, Norman G, Trop I. Randomized controlled trials. *AJR Am J Roentgenol* 2004;183:1539-44.doi:10.2214/ajr.183.6.01831539.
- 3 Bigna JJ, Noubiap JJ, Asangbeh SL, et al. Abstracts reporting of HIV/AIDS randomized controlled trials in general medicine and infectious diseases journals: completeness to date and improvement in the quality since CONSORT extension for abstracts. *BMC Med Res Methodol* 2016;16:138.doi:10.1186/s12874-016-0243-y.
- 4 The impact of open access upon public health. *PLoS Med* 2006;3:e252.doi:10.1371/journal.pmed.0030252.
- 5 Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 2008;5:e20.doi:10.1371/journal.pmed.0050020.
- 6 Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA* 1996;276:637-9
- 7 Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. *BMC Med Res Methodol* 2001;1:2
- 8 Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.doi:10.1136/bmj.c869.
- 9 Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010;11:32.doi:10.1186/1745-6215-11-32.
- 10 Chen Y, Li J, Ai C, et al. Assessment of the quality of reporting in abstracts of randomized controlled trials published in five leading Chinese medical journals. *PLoS One* 2010;5:e11926.doi:10.1371/journal.pone.0011926.
- 11 Berwanger O, Ribeiro RA, Finkelsztejn A, et al. The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals. *J Clin Epidemiol* 2009;62:387-92.doi:10.1016/j.jclinepi.2008.05.013.
- 12 Ghimire S, Kyung E, Kang W, et al. Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals. *Trials* 2012;13:77.doi:10.1186/1745-6215-13-77.
- 13 Knobloch K, Vogt PM. Adherence to CONSORT abstract reporting suggestions in surgical randomized-controlled trials published in *Annals of Surgery*. *Ann Surg* 2011;254:546; author reply -7.doi:10.1097/SLA.0b013e31822ad829.
- 14 Mbuagbaw L, Thabane M, Vanniyasingam T, et al. Improvement in the quality of abstracts in major clinical journals since CONSORT extension for abstracts: a systematic review. *Contemp Clin Trials* 2014;38:245-50.doi:10.1016/j.cct.2014.05.012.
- 15 Samaan Z, Mbuagbaw L, Kosa D, et al. A systematic scoping review of adherence to reporting guidelines in health care literature. *J Multidiscip Healthc* 2013;6:169-88.doi:10.2147/JMDH.S43952.
- 16 Can OS, Yilmaz AA, Hasdogan M, et al. Has the quality of abstracts for randomised controlled trials improved since the release of Consolidated Standards of Reporting Trial guideline for abstract reporting? A survey of four high-profile anaesthesia journals. *Eur J Anaesthesiol* 2011;28:485-92.doi:10.1097/EJA.0b013e32833fb96f.
- 17 Wang L, Li Y, Li J, et al. Quality of reporting of trial abstracts needs to be improved: using the CONSORT for abstracts to assess the four leading Chinese medical journals of traditional Chinese medicine. *Trials* 2010;11:75.doi:10.1186/1745-6215-11-75.
- 18 Chhapola V, Tiwari S, Brar R, et al. An interrupted time series analysis showed suboptimal improvement in reporting quality of trial abstract. *J Clin Epidemiol* 2016;71:11-7.doi:10.1016/j.jclinepi.2015.10.013.
- 19 Kiriakou J, Pandis N, Madianos P, et al. Assessing the reporting quality in abstracts of randomized controlled trials in leading journals of oral implantology. *J Evid Based Dent Pract* 2014;14:9-15.doi:10.1016/j.jebdp.2013.10.018.

- 1
2
3 20 Seehra J, Wright NS, Polychronopoulou A, et al. Reporting quality of abstracts of
4 randomized controlled trials published in dental specialty journals. *J Evid Based Dent Pract*
5 2013;13:1-8.doi:10.1016/j.jebdp.2012.11.001.
6 21 Hua F, Walsh T, Glenny AM, et al. Reporting quality of randomized controlled trial
7 abstracts presented at European Orthodontic Society congresses. *Eur J Orthod*
8 2016;38:584-92.doi:10.1093/ejo/cjv094.
9 22 Faggion CM, Jr., Giannakopoulos NN. Quality of reporting in abstracts of randomized
10 controlled trials published in leading journals of periodontology and implant dentistry: a
11 survey. *J Periodontol* 2012;83:1251-6.doi:10.1902/jop.2012.110609.
12 23 Ghimire S, Kyung E, Lee H, et al. Oncology trial abstracts showed suboptimal
13 improvement in reporting: a comparative before-and-after evaluation using CONSORT for
14 Abstract guidelines. *J Clin Epidemiol* 2014;67:658-66.doi:10.1016/j.jclinepi.2013.10.012.
15 24 Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal
16 neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report
17 no. 13. *Ophthalmology* 2004;111:1993-2006.doi:10.1016/j.ophtha.2004.07.023.
18 25 Baulig C, Krummenauer F, Knippschild S. [Evaluation of methodological quality in
19 published RCTs on cataract surgery : Pilot study on the degree of adherence to CONSORT
20 statement requirements and their qualitative validity]. *Ophthalmologe* 2018;115:40-
21 6.doi:10.1007/s00347-017-0446-6.
22 26 Blair DA, Hughes PJ, Woolley TW, Jr. Pharmacy journal abstracts published in PubMed
23 that abide by the CONSolidated Standards Of Reporting Trials (CONSORT) guidelines. *J*
24 *Med Libr Assoc* 2014;102:110-4.doi:10.3163/1536-5050.102.2.010.
25 27 Glasziuo P, Altman DG, Bossouyt P, et al. Reducing waste from incomplete or unusable
26 reports of biomedical research. *Lancet* 2014;383:257-66
27
28
29
30

31 **Acknowledgment**

32
33 The authors would like to thank Mrs Manuela Munk and Mrs Tara Rödter for linguistic
34 support in preparing this manuscript.
35
36
37
38
39

40 **Funding**

41
42 The authors are grateful to the Internal Research Foundation Initiative of the Witten /
43 Herdecke University's Faculty of Health, which enabled this investigation by means of a
44 supportive research grant comprising a one-year research position for Dr. Stephanie
45 Knippschild.
46
47
48
49
50

51 **Authors' Contributions**

52
53 Grant application: CB, SK, FK. Study conception and design: CB, SK, FK. Data collection:
54 CB, SK. Abstract selection: CB, SK. Data extraction: CB; SK. Statistical analysis: FK, BG,
55
56
57
58
59

1
2
3 ST. Data interpretation: CB, SK, FK, BG, ST. Drafting: CB. Critical discussion and
4 manuscript revision: FK, SK. Approval of final version: All authors.
5
6
7

8 **Data sharing statement** 9

10 The data may be obtained from the authors for academic purposes.
11
12
13
14

15 **Figure 1:**

16
17 Flowchart of the literature search and identification of randomized controlled clinical trial
18 abstracts, the exclusion of studies took place sequentially in the following order: no abstracts
19 available, not affiliated to AMD, inappropriate study design, no indication for randomisation.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Flowchart of the literature search and identification of randomized controlled clinical trial abstracts. The exclusion of studies took place sequentially in the following order: no abstracts available, not affiliated to AMD, inappropriate study design, no indication for randomisation.

45x34mm (300 x 300 DPI)

Supplement: Table S

Adherence of RCTs (N=136) to individual items of the CONSORT checklist for abstracts: declaration of items to be considered in the abstract according to the CONSORT recommendations, evaluation criteria for the respective abstracts, total and relative frequency [%] of abstracts providing information on the respective items according to the evaluation criteria; sub-items (* marked) are taken from Explanations and Elaborations of CONSORT for Abstracts checklist[5].

For peer review only

Item	assessment criteria	absolute and relative frequency of abstracts reporting the item (N = 136) (%)
Title	identification of the study as randomised	57 (42%)
Trial design	description of the trial design	97 (71%)
Participants	eligibility criteria for participants and setting where data was collected	123 (90%)
Interventions	were interventions intended for each group	129 (95%)
Objectives	specific objectives or hypotheses	133 (98%)
Definition primary outcome	clearly defined primary outcome	95 (70%)
Randomisation	How for this report participants were allocated to interventions	39 (29%)
Blinding (masking)	whether or not participants, caregivers and those assessing the outcomes were blinded to group assignment	59 (43%)
Numbers randomised	number of participants randomised to each group	75 (55%)
Recruitment	trial status	12 (9%)
Numbers analysed	number of participants analysed in each group	30 (22%)
Outcomes	fulfilling both criteria as:	0 (0%)
	– primary outcome for each trial group / trial arm*	87 (64%)
	– for primary outcome, effect size and precision (confidence interval) reported (in total)*	9 (7%)
Harms	important adverse events or side effects	65 (48%)
Conclusions	general interpretation of the results fulfilling both criteria:	23 (17%)
	– consistency with the results reported in the abstract*	130 (96%)
	– benefits and harms reported*	24 (18%)
Trial registration	registration number and name of trial register	26 (19%)
Funding	source of funding	33 (24%)

1
2
3 Recent queries in pubmed

4 Search,Query,Items found,Time

5 #12,"Search (((((macular degeneration) AND ("2004/01/01"[Date - Publication] : "2013/12/31"
6 [Date - Publication]))) AND english[Language])) AND "randomized controlled trial"[Publication Type]",673,
7 07:44:11

8
9 #11,"Search (((macular degeneration) AND ("2004/01/01"[Date - Publication] : "2013/12/31"
10 [Date - Publication]))) AND english[Language]",11737,07:44:00

11 #10,"Search (macular degeneration) AND ("2004/01/01"[Date - Publication] : "2013/12/31"
12 [Date - Publication])",13068,07:43:41

13 #1,"Search macular degeneration",22957,07:00:29
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Evaluated study abstracts [1-136]

- 1 Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. *Am J Ophthalmol* 2010;150:315-24 e1.doi:10.1016/j.ajo.2010.04.011.
- 2 Adjunctive Diclofenac with Verteporfin Study G, Boyer DS, Beer PM, et al. Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study. *Retina* 2007;27:693-700.doi:10.1097/IAE.0b013e318030e519.
- 3 Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, et al. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. *BMC Ophthalmol* 2005;5:27.doi:10.1186/1471-2415-5-27.
- 4 Ahmadi A, Ghanbari H, Soheilian M, et al. The EFFect of HESA-A (natural drug) on visual acuity in age related macular degeneration: a randomized double blind controlled clinical trial. *Afr J Tradit Complement Altern Med* 2009;6:549-53
- 5 Ahmadi H, Taei R, Riaz-Esfahani M, et al. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial. *Retina* 2011;31:1819-26.doi:10.1097/IAE.0b013e31820d58f2.
- 6 Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. *Am J Ophthalmol* 2008;145:862-74.doi:10.1016/j.ajo.2007.12.029.
- 7 Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. *Ophthalmology* 2006;113:2243-50.doi:10.1016/j.ophtha.2006.04.039.
- 8 Arnold C, Jentsch S, Dawczynski J, et al. Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study. *Nutrition* 2013;29:1412-7.doi:10.1016/j.nut.2013.05.012.
- 9 Arnold C, Winter L, Frohlich K, et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. *JAMA Ophthalmol* 2013;131:564-72.doi:10.1001/jamaophthalmol.2013.2851.
- 10 Augustin AJ, D'Amico DJ, Mieler WF, et al. Safety of posterior juxtasclear depot administration of the angiostatic cortisone anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2005;243:9-12.doi:10.1007/s00417-004-0961-4.
- 11 Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. *Arch Ophthalmol* 2005;123:448-57.doi:10.1001/archophth.123.4.448.
- 12 Barakat MR, Metelitsina TI, DuPont JC, et al. Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. *Curr Eye Res* 2006;31:629-34.doi:10.1080/02713680600760501.
- 13 Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. *Arch Ophthalmol* 2007;125:1357-61.doi:10.1001/archophth.125.10.1357.
- 14 Beatty S, Chakravarthy U, Nolan JM, et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. *Ophthalmology* 2013;120:600-6.doi:10.1016/j.ophtha.2012.08.040.
- 15 Berrow EJ, Bartlett HE, Eperjesi F, et al. The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy -- a randomised controlled trial. *Br J Nutr* 2013;109:2008-14.doi:10.1017/S0007114512004187.
- 16 Blaha M, Rencova E, Blaha V, et al. The importance of rheological parameters in the therapy of microcirculatory disorders. *Clin Hemorheol Microcirc* 2009;42:37-46.doi:10.3233/CH-2009-1184.

- 1
2
3 17 Blaha M, Rencova E, Langrova H, et al. Rheohaemapheresis in the treatment of nonvascular age-
4 related macular degeneration. *Atheroscler Suppl* 2013;14:179-
5 84.doi:10.1016/j.atherosclerosissup.2012.10.023.
6
7 18 Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in
8 subjects with neovascular age-related macular degeneration. *Ophthalmology* 2009;116:1731-
9 9.doi:10.1016/j.ophtha.2009.05.024.
10
11 19 Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of
12 age-related macular degeneration: ophthalmic findings: SST report no. 13. *Ophthalmology*
13 2004;111:1993-2006.doi:10.1016/j.ophtha.2004.07.023.
14
15 20 Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal
16 ranibizumab for recalcitrant neovascular macular degeneration-primary end point. *Ophthalmology*
17 2013;120:349-54.doi:10.1016/j.ophtha.2012.08.008.
18
19 21 Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular
20 endothelial growth factor trap-eye in wet age-related macular degeneration. *Ophthalmology*
21 2011;118:1089-97.doi:10.1016/j.ophtha.2011.02.039.
22
23 22 Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-
24 related macular degeneration. *N Engl J Med* 2006;355:1432-44.doi:10.1056/NEJMoa062655.
25
26 23 Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for
27 neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
28 *Ophthalmology* 2009;116:57-65 e5.doi:10.1016/j.ophtha.2008.10.018.
29
30 24 Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg
31 ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
32 *Ophthalmology* 2013;120:1046-56.doi:10.1016/j.ophtha.2012.10.014.
33
34 25 Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related
35 choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. *Lancet*
36 2013;382:1258-67.doi:10.1016/S0140-6736(13)61501-9.
37
38 26 Chang MA, Do DV, Bressler SB, et al. Prospective one-year study of ranibizumab for predominantly
39 hemorrhagic choroidal neovascular lesions in age-related macular degeneration. *Retina*
40 2010;30:1171-6.doi:10.1097/IAE.0b013e3181dd6d8a.
41
42 27 Chaudhary V, Mao A, Hooper PL, et al. Triamcinolone acetonide as adjunctive treatment to
43 verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
44 *Ophthalmology* 2007;114:2183-9.doi:10.1016/j.ophtha.2007.02.013.
45
46 28 Cohen SY, Bourgeois H, Corbe C, et al. Randomized clinical trial France DMLA2: effect of
47 trimetazidine on exudative and nonexudative age-related macular degeneration. *Retina* 2012;32:834-
48 43.doi:10.1097/IAE.0b013e31822058a3.
49
50 29 Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF,
51 Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular
52 degeneration: two-year results. *Ophthalmology* 2012;119:1388-
53 98.doi:10.1016/j.ophtha.2012.03.053.
54
55 30 Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined
56 with intravitreal bevacizumab for neovascular age-related macular degeneration. *Br J Ophthalmol*
57 2010;94:180-4.doi:10.1136/bjo.2009.159343.
58
59 31 Danis R, McLaughlin MM, Tolentino M, et al. Pazopanib eye drops: a randomised trial in
60 neovascular age-related macular degeneration. *Br J Ophthalmol* 2014;98:172-
8.doi:10.1136/bjophthalmol-2013-303117.
32 Dawczynski J, Jentsch S, Schweitzer D, et al. Long term effects of lutein, zeaxanthin and omega-3-
LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.
Graefes Arch Clin Exp Ophthalmol 2013;251:2711-23.doi:10.1007/s00417-013-2376-6.
33 Dugel PU, Bebbchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular
degeneration: a randomized, controlled trial (CABERNET). *Ophthalmology* 2013;120:317-
27.doi:10.1016/j.ophtha.2012.07.068.

- 1
2
3 34 Dunavoelgyi R, Sacu S, Simader C, et al. Changes in macular sensitivity after reduced fluence
4 photodynamic therapy combined with intravitreal triamcinolone. *Acta Ophthalmol* 2011;89:166-
5 71.doi:10.1111/j.1755-3768.2009.01646.x.
6
7 35 Eklund K, Sjostrand J, Dahlin-Ivanoff S. A randomized controlled trial of a health-promotion
8 programme and its effect on ADL dependence and self-reported health problems for the elderly
9 visually impaired. *Scand J Occup Ther* 2008;15:68-74.doi:10.1080/11038120701442963.
10
11 36 El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Fixed-interval versus OCT-guided variable dosing
12 of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a
13 12-month randomized prospective study. *Am J Ophthalmol* 2012;153:481-9
14 e1.doi:10.1016/j.ajo.2011.08.018.
15
16 37 Falkner-Radler CI, Krebs I, Glittenberg C, et al. Human retinal pigment epithelium (RPE)
17 transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a
18 randomised clinical study. *Br J Ophthalmol* 2011;95:370-5.doi:10.1136/bjo.2009.176305.
19
20 38 Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker
21 sensitivity in early age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2010;51:6118-
22 24.doi:10.1167/iovs.09-4995.
23
24 39 Feher J, Kovacs B, Kovacs I, et al. Improvement of visual functions and fundus alterations in early
25 age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids,
26 and coenzyme Q10. *Ophthalmologica* 2005;219:154-66.doi:10.1159/000085248.
27
28 40 Figueroa M, Schocket LS, DuPont J, et al. Long-term effect of laser treatment for dry age-related
29 macular degeneration on choroidal hemodynamics. *Am J Ophthalmol* 2006;141:863-
30 7.doi:10.1016/j.ajo.2005.11.049.
31
32 41 Flaxel C, Schain MB, Hamon SC, et al. Prospective randomized controlled trial of combination
33 ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a
34 pilot study. *Retina* 2012;32:417-23.doi:10.1097/IAE.0b013e318229b0af.
35
36 42 Frennesson CI, Bek T, Jaakkola A, et al. Prophylactic laser treatment of soft drusen maculopathy: a
37 prospective, randomized Nordic study. *Acta Ophthalmol* 2009;87:720-4.doi:10.1111/j.1755-
38 3768.2008.01396.x.
39
40 43 Friberg TR, Musch DC, Lim JI, et al. Prophylactic treatment of age-related macular degeneration
41 report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients.
42 *Ophthalmology* 2006;113:622 e1.doi:10.1016/j.ophtha.2005.10.066.
43
44 44 Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0
45 mg in the management of neovascular age-related macular degeneration in patients with
46 persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy
47 (the LAST Study). *Eye (Lond)* 2012;26:1181-7.doi:10.1038/eye.2012.174.
48
49 45 Garcia-Layana A, Recalde S, Alaman AS, et al. Effects of lutein and docosahexaenoic Acid
50 supplementation on macular pigment optical density in a randomized controlled trial. *Nutrients*
51 2013;5:543-51.doi:10.3390/nu5020543.
52
53 46 Gelisken F, Voelker M, Schwabe R, et al. Full macular translocation versus photodynamic therapy
54 with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of
55 a prospective, controlled, randomised pilot trial (FMT-PDT). *Graefes Arch Clin Exp Ophthalmol*
56 2007;245:1085-95.doi:10.1007/s00417-006-0524-y.
57
58 47 Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results
59 from a randomized clinical trial. *Arch Ophthalmol* 2004;122:336-40.doi:10.1001/archophth.122.3.336.
60
61 48 Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. Pegaptanib for neovascular age-related
62 macular degeneration. *N Engl J Med* 2004;351:2805-16.doi:10.1056/NEJMoa042760.
63
64 49 Group AHSR, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early
65 detection of choroidal neovascularization home monitoring of the Eye (HOME) study. *Ophthalmology*
66 2014;121:535-44.doi:10.1016/j.ophtha.2013.10.027.
67
68 50 Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-
69 related macular degeneration. *N Engl J Med* 2011;364:1897-908.doi:10.1056/NEJMoa1102673.
70

- 1
2
3 51 Group VISIONCT, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized
4 controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
5 *Ophthalmology* 2006;113:1508 e1-25.doi:10.1016/j.ophtha.2006.02.064.
6
7 52 Group VISIONCT, D'Amico DJ, Masonson HN, et al. Pegaptanib sodium for neovascular age-related
8 macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical
9 trials. *Ophthalmology* 2006;113:992-1001 e6.doi:10.1016/j.ophtha.2006.02.027.
10
11 53 Gustavsson C, Agardh E. Transpupillary thermotherapy for occult subfoveal choroidal
12 neovascularization: a 1-year, prospective randomized pilot study. *Acta Ophthalmol Scand*
13 2005;83:148-53.doi:10.1111/j.1600-0420.2005.00427.x.
14
15 54 Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled
16 study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One*
17 2013;8:e83759.doi:10.1371/journal.pone.0083759.
18
19 55 Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in
20 age-related macular degeneration: ophthalmic findings: SST report no. 11. *Ophthalmology*
21 2004;111:1967-80.doi:10.1016/j.ophtha.2004.07.021.
22
23 56 Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related
24 macular degeneration: a phase I/II multicenter, controlled, multidose study. *Ophthalmology*
25 2006;113:633 e1-4.doi:10.1016/j.ophtha.2005.10.052.
26
27 57 Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular
28 endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. *Ophthalmology*
29 2011;118:1098-106.doi:10.1016/j.ophtha.2011.03.020.
30
31 58 Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy
32 in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. *Arch*
33 *Ophthalmol* 2006;124:1532-42.doi:10.1001/archophth.124.11.1532.
34
35 59 Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related
36 macular degeneration. *Ophthalmology* 2012;119:2537-48.doi:10.1016/j.ophtha.2012.09.006.
37
38 60 Huang YM, Yan SF, Ma L, et al. Serum and macular responses to multiple xanthophyll supplements
39 in patients with early age-related macular degeneration. *Nutrition* 2013;29:387-
40 92.doi:10.1016/j.nut.2012.06.009.
41
42 61 Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat
43 neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
44 *Ophthalmology* 2012;119:1399-411.doi:10.1016/j.ophtha.2012.04.015.
45
46 62 Jaakkola A, Heikkinen J, Tommila P, et al. Strontium plaque brachytherapy for exudative age-
47 related macular degeneration: three-year results of a randomized study. *Ophthalmology*
48 2005;112:567-73.doi:10.1016/j.ophtha.2004.11.029.
49
50 63 Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related
51 macular degeneration: 52-week safety and efficacy results of the INTREPID study. *Ophthalmology*
52 2013;120:1893-900.doi:10.1016/j.ophtha.2013.02.016.
53
54 64 Jackson TL, Dugel PU, Bechuk JD, et al. Epimacular brachytherapy for neovascular age-related
55 macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
56 *Ophthalmology* 2013;120:1597-603.doi:10.1016/j.ophtha.2013.01.074.
57
58 65 Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal
59 neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
60 *Ophthalmology* 2012;119:1001-10.doi:10.1016/j.ophtha.2012.02.003.
61
62 66 Kaiser PK, Visudyne In Occult CNVsg. Verteporfin PDT for subfoveal occult CNV in AMD: two-year
63 results of a randomized trial. *Curr Med Res Opin* 2009;25:1853-60.doi:10.1185/03007990903038616.
64
65 67 Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for Neovascular Age-
66 related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
67 *Ophthalmology* 2013;120:2300-9.doi:10.1016/j.ophtha.2013.06.020.
68
69 68 Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual
70 outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related
71 macular degeneration. *Br J Ophthalmol* 2013;97:266-71.doi:10.1136/bjophthalmol-2012-302391.

- 1
2
3 69 Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus
4 combination of Ranibizumab with photodynamic therapy with neovascular age-related macular
5 degeneration. *Acta Ophthalmol* 2013;91:e178-83.doi:10.1111/aos.12018.
- 6 70 Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal
7 neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
8 *Ophthalmology* 2012;119:992-1000.doi:10.1016/j.ophtha.2012.02.002.
- 9 71 Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in
10 choroidal neovascularization due to age-related macular degeneration. *Ophthalmology*
11 2007;114:1179-85.doi:10.1016/j.ophtha.2007.03.006.
- 12 72 Lee J, Freeman WR, Azen SP, et al. Prospective, randomized clinical trial of intravitreal
13 triamcinolone treatment of neovascular age-related macular degeneration: one-year results. *Retina*
14 2007;27:1205-13.doi:10.1097/IAE.0b013e31815ec367.
- 15 73 Li X, Hu Y, Sun X, et al. Bevacizumab for neovascular age-related macular degeneration in China.
16 *Ophthalmology* 2012;119:2087-93.doi:10.1016/j.ophtha.2012.05.016.
- 17 74 Lushchik T, Amarakoon S, Martinez-Ciriano JP, et al. Bevacizumab in age-related macular
18 degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8
19 weeks. *Acta Ophthalmol* 2013;91:e456-61.doi:10.1111/aos.12119.
- 20 75 Ma L, Dou HL, Huang YM, et al. Improvement of retinal function in early age-related macular
21 degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-
22 controlled trial. *Am J Ophthalmol* 2012;154:625-34 e1.doi:10.1016/j.ajo.2012.04.014.
- 23 76 Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual
24 function in patients with early age-related macular degeneration. *Ophthalmology* 2012;119:2290-
25 7.doi:10.1016/j.ophtha.2012.06.014.
- 26 77 Maberley D, Canadian Retinal Trials G. Photodynamic therapy and intravitreal triamcinolone for
27 neovascular age-related macular degeneration: a randomized clinical trial. *Ophthalmology*
28 2009;116:2149-57 e1.doi:10.1016/j.ophtha.2009.04.032.
- 29 78 Marcus DM, Peskin E, Maguire M, et al. The age-related macular degeneration radiotherapy trial
30 (AMDRT): one year results from a pilot study. *Am J Ophthalmol* 2004;138:818-
31 28.doi:10.1016/j.ajo.2004.06.081.
- 32 79 Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic
33 atrophy in age-related macular degeneration. *Retina* 2013;33:498-
34 507.doi:10.1097/IAE.0b013e318265801d.
- 35 80 Menon G, Chandran M, Sivaprasad S, et al. Is it necessary to use three mandatory loading doses
36 when commencing therapy for neovascular age-related macular degeneration using bevacizumab?
37 (BeMOc Trial). *Eye (Lond)* 2013;27:959-63.doi:10.1038/eye.2013.93.
- 38 81 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of niacin on the choroidal circulation of
39 patients with age related macular degeneration. *Br J Ophthalmol* 2004;88:1568-
40 72.doi:10.1136/bjo.2004.046607.
- 41 82 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of Viagra on the foveolar choroidal circulation
42 of AMD patients. *Exp Eye Res* 2005;81:159-64.doi:10.1016/j.exer.2005.01.017.
- 43 83 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of viagra on retinal vein diameter in AMD
44 patients. *Exp Eye Res* 2006;83:128-32.doi:10.1016/j.exer.2005.11.012.
- 45 84 Michels S, Wachtlin J, Gamulescu MA, et al. Comparison of early retreatment with the standard
46 regimen in verteporfin therapy of neovascular age-related macular degeneration. *Ophthalmology*
47 2005;112:2070-5.doi:10.1016/j.ophtha.2005.06.034.
- 48 85 Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg
49 bevacizumab (Avastin) for treatment of CNV associated with AMD. *Retina* 2009;29:319-
50 24.doi:10.1097/IAE.0b013e318198148e.
- 51 86 Murray IJ, Makridaki M, van der Veen RL, et al. Lutein supplementation over a one-year period in
52 early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. *Invest Ophthalmol*
53 *Vis Sci* 2013;54:1781-8.doi:10.1167/iovs.12-10715.
- 54
55
56
57
58
59
60

- 1
2
3 87 Myint K, Armbrecht AM, Mon S, et al. Transpupillary thermotherapy for the treatment of occult
4 CNV in age-related macular degeneration: a prospective randomized controlled pilot study. *Acta*
5 *Ophthalmol Scand* 2006;84:328-32.doi:10.1111/j.1600-0420.2005.00623.x.
6
7 88 Neovascular Age-Related Macular Degeneration PC, Photodynamic Therapy Trial Research G,
8 Gilson MM, et al. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal
9 neovascularization in age-related macular degeneration. *Ophthalmology* 2007;114:1713-
10 21.doi:10.1016/j.optha.2007.03.071.
11
12 89 Nguyen QD, Campochiaro PA, Shah SM, et al. Evaluation of very high- and very low-dose
13 intravitreal aflibercept in patients with neovascular age-related macular degeneration. *J Ocul*
14 *Pharmacol Ther* 2012;28:581-8.doi:10.1089/jop.2011.0261.
15
16 90 Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus
17 ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
18 *Ophthalmology* 2012;119:1867-73.doi:10.1016/j.optha.2012.03.043.
19
20 91 Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial
21 growth factor trap for treatment in patients with choroidal neovascularization due to age-related
22 macular degeneration. *Ophthalmology* 2006;113:1522 e1- e14.doi:10.1016/j.optha.2006.05.055.
23
24 92 Nussenblatt RB, Byrnes G, Sen HN, et al. A randomized pilot study of systemic immunosuppression
25 in the treatment of age-related macular degeneration with choroidal neovascularization. *Retina*
26 2010;30:1579-87.doi:10.1097/IAE.0b013e3181e7978e.
27
28 93 Odergren A, Algvere PV, Seregard S, et al. A prospective randomised study on low-dose
29 transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular
30 degeneration. *Br J Ophthalmol* 2008;92:757-61.doi:10.1136/bjo.2007.133561.
31
32 94 Parodi MB, Toto L, Mastropasqua L, et al. Prismatic correction in patients affected by age-related
33 macular degeneration. *Clin Rehabil* 2004;18:828-32.doi:10.1191/0269215504cr801oa.
34
35 95 Piermarocchi S, Sartore M, Lo Giudice G, et al. Combination of photodynamic therapy and
36 intraocular triamcinolone for exudative age-related macular degeneration and long-term
37 chorioretinal macular atrophy. *Arch Ophthalmol* 2008;126:1367-
38 74.doi:10.1001/archophth.126.10.1367.
39
40 96 Piermarocchi S, Saviano S, Parisi V, et al. Carotenoids in Age-related Maculopathy Italian Study
41 (CARMIS): two-year results of a randomized study. *Eur J Ophthalmol* 2012;22:216-
42 25.doi:10.5301/ejo.5000069.
43
44 97 Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose
45 photodynamic therapy in age-related macular degeneration: the VIA study. *Br J Ophthalmol*
46 2010;94:174-9.doi:10.1136/bjo.2008.155531.
47
48 98 Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of
49 rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. *Trans Am*
50 *Ophthalmol Soc* 2006;104:221-31
51
52 99 Ranchod TM, Ray SK, Daniels SA, et al. LuceDex: a prospective study comparing ranibizumab plus
53 dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related
54 macular degeneration. *Retina* 2013;33:1600-4.doi:10.1097/IAE.0b013e318285cb71.
55
56 100 Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of
57 ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. *Am J Ophthalmol*
58 2008;145:239-48.doi:10.1016/j.ajo.2007.10.004.
59
60 101 Rencova E, Blaha M, Studnicka J, et al. Haemorheopheresis could block the progression of the
dry form of age-related macular degeneration with soft drusen to the neovascular form. *Acta*
Ophthalmol 2011;89:463-71.doi:10.1111/j.1755-3768.2009.01710.x.
102 Richer S, Devenport J, Lang JC. LAST II: Differential temporal responses of macular pigment
optical density in patients with atrophic age-related macular degeneration to dietary
supplementation with xanthophylls. *Optometry* 2007;78:213-9.doi:10.1016/j.optm.2006.10.019.
103 Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of
lutein and antioxidant supplementation in the intervention of atrophic age-related macular
degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). *Optometry*
2004;75:216-30

- 1
2
3 104 Richer SP, Stiles W, Graham-Hoffman K, et al. Randomized, double-blind, placebo-controlled
4 study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration:
5 the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. *Optometry* 2011;82:667-80
6 e6.doi:10.1016/j.optm.2011.08.008.
7
8 105 Rosenfeld PJ, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal occult choroidal
9 neovascularization in AMD using delayed light application: one-year results of the VALIO Study. *Am J*
10 *Ophthalmol* 2007;144:970-2.doi:10.1016/j.ajo.2007.08.017.
11
12 106 Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular
13 degeneration. *N Engl J Med* 2006;355:1419-31.doi:10.1056/NEJMoa054481.
14
15 107 Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses
16 of ranibizumab (Lucentis) for neovascular age-related macular degeneration. *Ophthalmology*
17 2006;113:623 e1.doi:10.1016/j.ophtha.2006.01.027.
18
19 108 Rosenthal JM, Kim J, de Monasterio F, et al. Dose-ranging study of lutein supplementation in
20 persons aged 60 years or older. *Invest Ophthalmol Vis Sci* 2006;47:5227-33.doi:10.1167/iovs.05-
21 1513.
22
23 109 Russo A, Costagliola C, Delcassi L, et al. A randomised controlled trial of ranibizumab with and
24 without ketorolac eyedrops for exudative age-related macular degeneration. *Br J Ophthalmol*
25 2013;97:1273-6.doi:10.1136/bjophthalmol-2013-303417.
26
27 110 Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic
28 therapy and intravitreal triamcinolone: long-term results. *Eye (Lond)* 2009;23:2223-
29 7.doi:10.1038/eye.2008.423.
30
31 111 Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in
32 combination with intravitreal triamcinolone: short-term results of a randomised study. *Br J*
33 *Ophthalmol* 2008;92:1347-51.doi:10.1136/bjo.2008.137885.
34
35 112 Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of
36 predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
37 *Retina* 2010;30:1390-9.doi:10.1097/IAE.0b013e3181e44599.
38
39 113 Sarraf D, Chan C, Rahimy E, et al. Prospective evaluation of the incidence and risk factors for the
40 development of RPE tears after high- and low-dose ranibizumab therapy. *Retina* 2013;33:1551-
41 7.doi:10.1097/IAE.0b013e31828992f5.
42
43 114 Schmid-Kubista KE, Krebs I, Ansari-Shahrezaei S, et al. Comparing treatment of neovascular age-
44 related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal
45 mono-therapy--a pilot study. *Curr Eye Res* 2011;36:958-63.doi:10.3109/02713683.2011.597536.
46
47 115 Schmid-Kubista KE, Krebs I, Gruenberger B, et al. Systemic bevacizumab (Avastin) therapy for
48 exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. *Br J Ophthalmol*
49 2009;93:914-9.doi:10.1136/bjo.2008.144410.
50
51 116 Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly
52 ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
53 *Ophthalmology* 2011;118:831-9.doi:10.1016/j.ophtha.2010.09.004.
54
55 117 Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for
56 neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
57 *Ophthalmology* 2014;121:193-201.doi:10.1016/j.ophtha.2013.08.011.
58
59 118 Schmidt-Erfurth U, Sacu S, Early Retreatment Study G. Randomized multicenter trial of more
60 intense and standard early verteporfin treatment of neovascular age-related macular degeneration.
Ophthalmology 2008;115:134-40.doi:10.1016/j.ophtha.2007.02.033.
119 Schmidt-Erfurth UM, Elsner H, Terai N, et al. Effects of verteporfin therapy on central visual field
function. *Ophthalmology* 2004;111:931-9.doi:10.1016/j.ophtha.2003.12.025.
120 Sin M, Chrapek O, Karhanova M, et al. Progression of macular atrophy after PDT combined with
the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD. *Biomed Pap Med Fac Univ*
Palacky Olomouc Czech Repub 2014;158:138-43.doi:10.5507/bp.2012.066.
121 Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related
macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular
Neovascularisation (VISION) trial. *Br J Ophthalmol* 2008;92:1606-11.doi:10.1136/bjo.2007.132597.

- 1
2
3 122 Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus
4 photodynamic therapy for treatment of subfoveal neovascularization in age-related macular
5 degeneration. *Ophthalmology* 2006;113:3-13.doi:10.1016/j.ophtha.2005.10.019.
6
7 123 Soderberg AC, Algvere PV, Hengstler JC, et al. Combination therapy with low-dose transpupillary
8 thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-
9 month prospective randomised clinical study. *Br J Ophthalmol* 2012;96:714-
10 8.doi:10.1136/bjophthalmol-2011-300721.
11 124 Souayah N, Khella SL. A prospective double-blind, placebo-controlled study of thalidomide
12 sensory symptoms in an elderly population with age-related macular degeneration. *J Clin Neurosci*
13 2010;17:571-3.doi:10.1016/j.jocn.2009.09.017.
14 125 Souied EH, Delcourt C, Querques G, et al. Oral docosahexaenoic acid in the prevention of
15 exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study.
16 *Ophthalmology* 2013;120:1619-31.doi:10.1016/j.ophtha.2013.01.005.
17 126 Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular
18 degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. *Eye (Lond)*
19 2010;24:1708-15.doi:10.1038/eye.2010.147.
20 127 Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular
21 degeneration: early results of a prospective double-masked, randomized clinical trial. *Am J*
22 *Ophthalmol* 2009;148:875-82 e1.doi:10.1016/j.ajo.2009.07.009.
23 128 Sun YD, Dong YD, Fan R, et al. Effect of (R)-alpha-lipoic acid supplementation on serum lipids and
24 antioxidative ability in patients with age-related macular degeneration. *Ann Nutr Metab*
25 2012;60:293-7.doi:10.1159/000338444.
26 129 Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration
27 (ABC Trial): multicentre randomised double masked study. *BMJ*
28 2010;340:c2459.doi:10.1136/bmj.c2459.
29 130 Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory
30 study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal
31 ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. *Eye*
32 *(Lond)* 2010;24:1561-7.doi:10.1038/eye.2010.84.
33 131 Weigert G, Kaya S, Pemp B, et al. Effects of lutein supplementation on macular pigment optical
34 density and visual acuity in patients with age-related macular degeneration. *Invest Ophthalmol Vis Sci*
35 2011;52:8174-8.doi:10.1167/iovs.11-7522.
36 132 Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus
37 photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular
38 degeneration: 6-month results of a prospective, randomised, controlled clinical study. *Br J*
39 *Ophthalmol* 2008;92:356-60.doi:10.1136/bjo.2007.125823.
40 133 Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with
41 eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.
42 *Ophthalmology* 2014;121:693-701.doi:10.1016/j.ophtha.2013.09.044.
43 134 Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related
44 macular degeneration. *Ophthalmology* 2006;113:2012-9.doi:10.1016/j.ophtha.2006.05.036.
45 135 Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell
46 intraocular implants for treatment of geographic atrophy in age-related macular degeneration. *Proc*
47 *Natl Acad Sci U S A* 2011;108:6241-5.doi:10.1073/pnas.1018987108.
48 136 Ziemssen F, Luke M, Bartz-Schmidt KU, et al. Time-dependent effects on contrast sensitivity, near
49 and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of
50 photodynamic therapy versus full macular translocation). *Graefes Arch Clin Exp Ophthalmol*
51 2008;246:653-9.doi:10.1007/s00417-007-0726-y.
52
53
54
55
56
57
58
59
60



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	3
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	--
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	--
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	--
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19/3

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.